WO2010114106A1 - ヒトサイトメガロウイルスgB糖タンパク質のAD1領域に存在する特定の不連続エピトープに結合するモノクローナル抗体ならびにその抗原結合性断片 - Google Patents
ヒトサイトメガロウイルスgB糖タンパク質のAD1領域に存在する特定の不連続エピトープに結合するモノクローナル抗体ならびにその抗原結合性断片 Download PDFInfo
- Publication number
- WO2010114106A1 WO2010114106A1 PCT/JP2010/056037 JP2010056037W WO2010114106A1 WO 2010114106 A1 WO2010114106 A1 WO 2010114106A1 JP 2010056037 W JP2010056037 W JP 2010056037W WO 2010114106 A1 WO2010114106 A1 WO 2010114106A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- hcmv
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title claims abstract description 178
- 230000027455 binding Effects 0.000 title claims abstract description 144
- 239000000427 antigen Substances 0.000 title claims abstract description 109
- 102000036639 antigens Human genes 0.000 title claims abstract description 109
- 108091007433 antigens Proteins 0.000 title claims abstract description 109
- 239000012634 fragment Substances 0.000 title claims abstract description 103
- 102000003886 Glycoproteins Human genes 0.000 title claims abstract description 54
- 108090000288 Glycoproteins Proteins 0.000 title claims abstract description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 57
- 201000010099 disease Diseases 0.000 claims abstract description 54
- 208000015181 infectious disease Diseases 0.000 claims abstract description 49
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 48
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 502
- 238000006467 substitution reaction Methods 0.000 claims description 78
- 125000000539 amino acid group Chemical group 0.000 claims description 70
- 210000004027 cell Anatomy 0.000 claims description 54
- 238000012217 deletion Methods 0.000 claims description 46
- 230000037430 deletion Effects 0.000 claims description 46
- 150000001413 amino acids Chemical class 0.000 claims description 43
- 238000003780 insertion Methods 0.000 claims description 40
- 230000037431 insertion Effects 0.000 claims description 40
- 238000007792 addition Methods 0.000 claims description 38
- 150000007523 nucleic acids Chemical class 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 35
- 108020004707 nucleic acids Proteins 0.000 claims description 35
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 28
- 230000004071 biological effect Effects 0.000 claims description 27
- 230000035772 mutation Effects 0.000 claims description 19
- 206010010430 Congenital cytomegalovirus infection Diseases 0.000 claims description 16
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 16
- 238000011161 development Methods 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 14
- 210000002950 fibroblast Anatomy 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 230000034994 death Effects 0.000 claims description 12
- 206010038910 Retinitis Diseases 0.000 claims description 10
- 208000005577 Gastroenteritis Diseases 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 206010014599 encephalitis Diseases 0.000 claims description 8
- 208000016354 hearing loss disease Diseases 0.000 claims description 8
- 206010000234 Abortion spontaneous Diseases 0.000 claims description 7
- 206010023126 Jaundice Diseases 0.000 claims description 7
- 201000004709 chorioretinitis Diseases 0.000 claims description 7
- 210000003754 fetus Anatomy 0.000 claims description 7
- 206010019847 hepatosplenomegaly Diseases 0.000 claims description 7
- 208000015994 miscarriage Diseases 0.000 claims description 7
- 230000007420 reactivation Effects 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 208000000995 spontaneous abortion Diseases 0.000 claims description 7
- 208000002254 stillbirth Diseases 0.000 claims description 7
- 231100000537 stillbirth Toxicity 0.000 claims description 7
- 206010061598 Immunodeficiency Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 208000018773 low birth weight Diseases 0.000 claims description 6
- 231100000533 low birth weight Toxicity 0.000 claims description 6
- 208000004141 microcephaly Diseases 0.000 claims description 6
- 208000012239 Developmental disease Diseases 0.000 claims description 5
- 230000003111 delayed effect Effects 0.000 claims description 5
- 230000003340 mental effect Effects 0.000 claims description 5
- 230000007505 plaque formation Effects 0.000 claims description 5
- 206010010356 Congenital anomaly Diseases 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 2
- 230000005976 liver dysfunction Effects 0.000 claims description 2
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 15
- 235000001014 amino acid Nutrition 0.000 description 66
- 108090000765 processed proteins & peptides Proteins 0.000 description 62
- 238000000034 method Methods 0.000 description 51
- 229940024606 amino acid Drugs 0.000 description 41
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 35
- 229960002429 proline Drugs 0.000 description 35
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 31
- 230000000694 effects Effects 0.000 description 30
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 28
- 229960000310 isoleucine Drugs 0.000 description 23
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 21
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 20
- 229960004295 valine Drugs 0.000 description 19
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 18
- 239000004474 valine Substances 0.000 description 18
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 17
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 16
- 235000003704 aspartic acid Nutrition 0.000 description 16
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 16
- 229960003136 leucine Drugs 0.000 description 16
- 239000004471 Glycine Substances 0.000 description 15
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 15
- 210000000628 antibody-producing cell Anatomy 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 14
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 13
- 235000004279 alanine Nutrition 0.000 description 13
- 239000012228 culture supernatant Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 235000013922 glutamic acid Nutrition 0.000 description 13
- 239000004220 glutamic acid Substances 0.000 description 13
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-Valine Natural products CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 12
- 108010076504 Protein Sorting Signals Proteins 0.000 description 12
- 229960003767 alanine Drugs 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 11
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 11
- 229960004452 methionine Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 10
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 10
- 239000004473 Threonine Substances 0.000 description 10
- 229930182817 methionine Natural products 0.000 description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 10
- 239000004475 Arginine Substances 0.000 description 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 229960002963 ganciclovir Drugs 0.000 description 9
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 230000003449 preventive effect Effects 0.000 description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- 229960001230 asparagine Drugs 0.000 description 8
- 235000009582 asparagine Nutrition 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 230000016784 immunoglobulin production Effects 0.000 description 8
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 208000030507 AIDS Diseases 0.000 description 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 229940125644 antibody drug Drugs 0.000 description 7
- 150000001510 aspartic acids Chemical class 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 201000006747 infectious mononucleosis Diseases 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 5
- -1 L-valine ester Chemical class 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010322 bone marrow transplantation Methods 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000001631 haemodialysis Methods 0.000 description 5
- 230000000322 hemodialysis Effects 0.000 description 5
- 229960002885 histidine Drugs 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 5
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 229940126585 therapeutic drug Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 4
- 206010007269 Carcinogenicity Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 206010043275 Teratogenicity Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000001261 affinity purification Methods 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 150000001508 asparagines Chemical class 0.000 description 3
- 230000007670 carcinogenicity Effects 0.000 description 3
- 231100000260 carcinogenicity Toxicity 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 229940075234 cytogam Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 229960005102 foscarnet Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 108010074605 gamma-Globulins Proteins 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 231100000211 teratogenicity Toxicity 0.000 description 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102220520567 Glypican-1_N79Q_mutation Human genes 0.000 description 2
- 241000700586 Herpesviridae Species 0.000 description 2
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 2
- 241000701027 Human herpesvirus 6 Species 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 230000001512 anti-cytomegaloviral effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 229940098197 human immunoglobulin g Drugs 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229960002149 valganciclovir Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- YOFPFYYTUIARDI-ZCFIWIBFSA-N (2r)-2-aminooctanedioic acid Chemical compound OC(=O)[C@H](N)CCCCCC(O)=O YOFPFYYTUIARDI-ZCFIWIBFSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000272186 Falco columbarius Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010018999 Haemorrhage subcutaneous Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- KNTFCRCCPLEUQZ-VKHMYHEASA-N O-methylserine Chemical compound COC[C@H](N)C(O)=O KNTFCRCCPLEUQZ-VKHMYHEASA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001129119 Panine betaherpesvirus 2 Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040021 Sensory abnormalities Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010029389 Simplexvirus glycoprotein B Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043431 Thinking abnormal Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- ZORWARFPXPVJLW-MTFPJWTKSA-N [2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]-3-hydroxypropyl] (2s)-2-amino-3-methylbutanoate;hydron;chloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 ZORWARFPXPVJLW-MTFPJWTKSA-N 0.000 description 1
- OBABDJMYPMAQEP-UHFFFAOYSA-N [[2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]-3-hydroxypropoxy]-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=N2 OBABDJMYPMAQEP-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940002080 cytomegalovirus immune globulin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000021245 head disease Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- BBJIPMIXTXKYLZ-UHFFFAOYSA-N isoglutamic acid Chemical compound OC(=O)CC(N)CC(O)=O BBJIPMIXTXKYLZ-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000005892 protein maturation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229960004983 valganciclovir hydrochloride Drugs 0.000 description 1
- 150000003679 valine derivatives Chemical class 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000008478 viral entry into host cell Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to a monoclonal antibody that binds to human cytomegalovirus (hereinafter sometimes referred to as “HCMV”), and an antigen-binding fragment thereof.
- HCMV human cytomegalovirus
- it relates to human monoclonal antibodies that bind to the AD1 region of the HCMV gB glycoprotein and antigen-binding fragments thereof.
- HCMV Human cytomegalovirus
- HHV-6 human herpesvirus 6
- HHV-7 human herpesvirus 7
- HHV-6 human herpesvirus 6
- HHV-7 human herpesvirus 7
- HCMV is highly species-specific and does not infect animals other than humans, but is widely infected in humans and has affinity for a wide range of tissues in the human body. Moreover, once infected, it is retained throughout its life without being eliminated even after immunity of the host is established.
- HCMV is a latent infection throughout life, and more than 90% of Japanese adults are already infected and carry the virus.
- immunocompromised states such as AIDS, cancer, organ transplantation, bone marrow transplantation, and hemodialysis
- reactivation of this latently infected HCMV occurs, causing interstitial pneumonia, retinitis, gastroenteritis, It can cause severe HCMV infections, such as encephalitis, which can be fatal (Non-Patent Documents 3 and 4).
- congenital cytomegalovirus disease congenital cytomegalovirus disease
- Also called cytomegalic inclusion disease congenital cytomegalovirus disease
- miscarriage stillbirth, and death just after birth.
- Non-Patent Documents 3, 4, and 5 disclose HCMV infection via the birth canal, breast milk, urine, saliva, etc.
- HCMV infection via the birth canal, breast milk, urine, saliva, etc. causes liver function abnormalities, interstitial pneumonia, In some cases, nucleosis or the like develops (Non-Patent Documents 3, 4, and 5).
- HCMV infection is a worldwide problem, and the development of preventive or therapeutic drugs capable of suppressing or alleviating the onset of various pathologies caused by the HCMV is being promoted.
- ganciclovir Non-patent documents 6 and 7
- foscarnet non-patent document 8
- valganciclovir non-patent document 9
- Ganciclovir becomes an active form of ganciclovir-triphosphate in the cell and inhibits DNA polymerase by competitively antagonizing with DNA polymerase substrate deoxyguanosine-triphosphate (dGTP), thereby inhibiting viral DNA.
- dGTP DNA polymerase substrate deoxyguanosine-triphosphate
- Antiviral drugs that interfere with synthesis, mainly treating cytomegalovirus retinitis in immunocompromised states such as AIDS, and suppressing the onset of cytomegalovirus retinitis in advanced HIV infection with CD4 lymphocyte counts of 100 / mm 3 or less It is also used as a pharmaceutical product.
- antiviral agents such as ganciclovir have various side effects such as hematopoietic disorder, and the usage mode is limited as described above.
- ganciclovir blood disorders associated with bone marrow suppression that require attention.
- Leukocytes, red blood cells, and platelets are abnormally decreased, and initial symptoms include fever, sore throat, abnormal dullness, and bleeding tendency such as subcutaneous bleeding.
- abnormalities are found in the neuropsychiatric system, causing headache, dizziness, insomnia, abnormal thinking, anxiety, and the like.
- teratogenicity, mutagenicity, and carcinogenicity have been reported and cannot be used during pregnancy.
- the use of ganciclovir in severe cases of congenital HCMV infection is said to have the effect of reducing the development of neurological sequelae and improving the progression of hearing loss (Non-patent Document 10).
- Valganciclovir is an L-valine ester of gancyclyl and is orally administered and then converted to ganciclovir by intestinal and liver esterases. Therefore, the mechanism of action and side effects are the same as those of ganciclovir, and there are problems of myelosuppression, teratogenicity, and carcinogenicity. Is obtained.
- foscarnet inhibits the growth of HCMV by inhibiting the DNA polymerase by acting directly on the pyrophosphate binding site of the DNA polymerase with an analog of pyrophosphate. It is also effective against gancvvir resistant HCMV.
- Major side effects include nausea, anemia, elevated serum creatinine, vomiting, hypomagnesemia, hypokalemia, and sensory abnormalities. Especially, shock and nephropathy occur frequently, so careful medication is necessary. . In Japan, it is approved for use only in patients with AIDS who have been diagnosed with HCMV retinitis or clinically strongly suspected of having HCMV retinitis. Reference 8).
- Non-patent Document 11 Non-patent Document 11
- HCMV vaccine development has been conducted eagerly, there is still no product that can withstand clinical use.
- human-derived anti-CMV high-titer gamma globulin preparations have been developed, and in the United States, they have been approved for the indication of prevention of HCMV infection associated with kidney transplantation.
- the anti-CMV high titer gamma globulin preparation is a human blood preparation, it has various problems.
- anti-HCMV antibody a monoclonal antibody that can bind to HCMV and neutralize its infectivity (can lose its biological activity)
- anti-HCMV antibody a monoclonal antibody that can bind to HCMV and neutralize its infectivity (can lose its biological activity)
- a human-derived anti-HCMV antibody that has a strong affinity for HCMV, a high neutralizing ability, and does not exhibit an allergic reaction in order to prevent or alleviate symptoms by losing the activity of HCMV Is considered to be particularly effective as a so-called “antibody drug”.
- HCMV inhibitory antibodies for example, Patent Documents 1, 2, 3, 4, and 5
- Patent Documents 1, 2, 3, 4, and 5 reported to date have not been sufficient in terms of affinity and neutralizing ability for HCMV. It has not been possible to expect to sufficiently block the biological activity of HCMV, prevent the onset of various diseases caused by HCMV, or alleviate the symptoms. Therefore, an anti-HCMV antibody that is a human monoclonal antibody that does not cause a foreign body recognition response, has excellent affinity, specificity, and neutralizing ability for HCMV, and can be expected to be used as a preventive or therapeutic agent, and Development of the antigen-binding fragment has been strongly desired.
- Non-patent Documents 12 and 13 Recently, in order to suppress the growth of HCMV in vivo, it has been pointed out that not only neutralization activity but also prevention of intercellular infection has been pointed out (Non-patent Documents 12 and 13). An anti-HCMV antibody having an infection inhibitory activity has been eagerly desired.
- antibodies or antigen-binding fragments that specifically bind to HCMV and sufficiently inhibit its biological activity are useful in therapeutic strategies or preventive strategies for various diseases caused by HCMV. It is thought that.
- HCMV is inherently infectious in a wide range of tissues and cell types in the body (Sinzger, C.
- the anti-HCMV antibody is eagerly desired to have not only a neutralizing ability but also an ability to inhibit intercellular infection. Furthermore, considering the effectiveness and safety as a pharmaceutical, human-derived monoclonal antibody having high neutralizing ability and ability to prevent intercellular infection and its antigen-binding ability against HCMV that causes various disease states It would be desirable to provide pharmaceutical compositions containing the fragments.
- the present inventors specifically recognize an unreported discontinuous epitope present in the AD1 region on the HCMV gB glycoprotein, The present invention was completed by successfully obtaining a human monoclonal antibody having both high neutralizing ability and high ability to inhibit intercellular infection.
- the present invention relates to an anti-HCMV monoclonal antibody or a binding fragment thereof, a DNA (polynucleotide) encoding the antibody or binding fragment, a vector containing the DNA, and a host cell containing the vector described below. And so on.
- An antibody or antigen-binding fragment thereof that binds to the AD1 region of human cytomegalovirus (HCMV) gB glycoprotein, the amino acid sequence of SEQ ID NO: 25, the amino acid sequence of SEQ ID NO: 26, which is present in the AD1 region;
- An antibody or antigen-binding fragment thereof that recognizes a discontinuous sequence consisting of the amino acid sequence of SEQ ID NO: 27 as an epitope.
- variable region of the heavy chain is (a) having the amino acid sequence of SEQ ID NO: 13 and deletion, substitution, insertion, addition of one or several amino acid residues in the amino acid sequence of SEQ ID NO: 13, or a combination of any two or more thereof
- An amino acid sequence of a heavy chain CDR1 selected from the group consisting of amino acid sequences (b) having the amino acid sequence of SEQ ID NO: 14 and deletion, substitution, insertion, addition of one or several amino acid residues in the amino acid sequence of SEQ ID NO: 14, or a combination of any two or more thereof
- An amino acid sequence of a heavy chain CDR2 selected from the group consisting of the amino acid sequences; and (c) the amino acid sequence of SEQ ID NO: 15, an amino acid having a deletion, substitution, insertion, addition of one or several amino acid residues in the amino acid sequence of
- [5] The antibody or antigen-binding fragment thereof according to [3] or [4] above, (I) (a) the amino acid sequence of heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13, (b) the amino acid sequence of heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and (c) the amino acid sequence of heavy chain CDR3 selected from the group consisting of the amino acid sequence of SEQ ID NO: 22, and (ii) (a) the amino acid sequence of light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 16, (b) the amino acid sequence of light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 17, and (c) the amino acid sequence of light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 18, Or an antigen-binding fragment thereof.
- the 50% plaque formation inhibitory concentration under human fibroblasts is 0.05 ⁇ g / mL (about 0.3 nM) or less against the laboratory strain (AD169) of HCMV Or an antigen-binding fragment thereof.
- HCMV human cytomegalovirus
- a pharmaceutical composition for [16] Diseases involving HCMV are: (a) interstitial pneumonia, retinitis, gastroenteritis, or encephalitis due to reactivation of HCMV in an immunocompromised state, (b) HCMV infection spread from pregnant woman to fetus (C) miscarriage, stillbirth, short-term death caused by the congenital CMV infection, (d) low birth weight in cases where the congenital CMV infection does not result in death, hepatosplenomegaly, Jaundice, thrombocytopenic purpura, microcephaly, mental developmental disorder, delayed intellectual development, chorioretinitis, or hearing impairment, or (e) liver dysfunction caused by HCMV infection in neonates or infants, interstitial pneumonia Or the pharmaceutical composition according
- a nucleic acid encoding an anti-HCMV monoclonal antibody or antigen-binding fragment thereof capable of specifically binding to the AD1 region of HCMV gB glycoprotein and neutralizing its biological activity comprising SEQ ID NOs: 2, 4, 6,
- the anti-HCMV antibody according to the present invention in particular, an antibody that specifically binds to the AD1 region of HCMV-gB glycoprotein, or an antigen-binding fragment thereof, is specific for HCMV that causes various diseases, for example, in an immunodeficient state. It binds and loses (neutralizes) its biological activity and exhibits an excellent neutralizing ability for HCMV.
- the anti-HCMV-gB glycoprotein AD1 antibody according to the present invention is a human monoclonal antibody, there is an advantage that it has no immunogenicity and no immune reaction.
- One embodiment of the anti-HCMV antibody according to the present invention also has high cell-cell infection inhibitory activity or cell-cell infection inhibitory activity against HCMV. Considering the mode of infection spread of HCMV in vivo, it is advantageous that the anti-HCMV antibody has not only a neutralizing ability but also an intercellular infection inhibiting ability.
- the anti-HCMV antibody or antigen-binding fragment thereof according to the present invention has a high neutralizing ability and infection spreading inhibitory activity against HCMV, and is not immunogenic for human monoclonal antibody embodiments.
- composition containing a human monoclonal antibody according to the present invention is effective in an extremely small amount.
- an antibody that specifically binds to the AD1 region of gB glycoprotein and has high neutralizing activity is very useful as a preventive or therapeutic agent for HCMV infection.
- Non-patent Documents 12 and 13 In order to suppress the growth of viruses such as HCMV in vivo, importance of not only neutralizing activity but also prevention of intercellular infection has been pointed out (Non-patent Documents 12 and 13). GB glycoproteins have been shown to play an important role in the entry and intercellular infection of viral particles (Isaacson, MK et al., Human cytomegalovirus glycoprotein B is required). for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. J. Virology, 2009; 83: p3891-3903), antibodies against gB are likely to contribute to inhibition of intercellular infection .
- the AD1 region is an essential part for the formation of gB function and conformation (Qadri, I. et al., Assembly of conformational-dependent neutralizing domains on glycoprotein).
- it is known as a part with few mutations even in clinically isolated virus strains, and an antibody against AD1 may have a broad spectrum.
- the AD1 antibody that recognizes a discontinuous epitope extending over a long region on gB has high specificity and is less likely to cause unexpected side effects due to cross-reaction with other biomolecules. it is conceivable that.
- amino acids constituting EV2038 CDR-H3 amino acid residues whose binding ability to AD1 has been reduced by non-conservative amino acid substitutions, except for the 125th proline (121, 123, 124, and 126th residues in total 4 residues) 4 types of variants in which two or four sites were simultaneously substituted were prepared (two-substitution: I124V / G126A, I124V / G126S, four-place substitution: L121I / W123Y / I124V / G126A, L121I / W123Y / I124V / G126S) and binding ability to AD1 were evaluated.
- amino acids constituting EV2038 CDR-H3 amino acid residues whose binding ability to AD1 is reduced by non-conservative amino acid substitution, except for 125th proline (121, 123, 124, and 126th total 4)
- 125th proline 121, 123, 124, and 126th total 4
- deletion and insertion variants were prepared (E122del and G126_D127insE), and the binding ability to AD1 was evaluated. This is an evaluation of the binding ability to AD1 in the variant of the 79th amino acid residue of the EV2038 CDR-H2 region.
- FIG. (A) illustrates clones of deletion mutants of the gB glycoprotein AD1 region used for the analysis of the epitope region, and (B) shows the results of Western blot analysis using these deletion variants.
- FIG. (A) is the figure which showed the result of the epitope mapping of EV2038 using a peptide array.
- the above analysis results are illustrated on the amino acid sequence of the gB glycoprotein, the analysis results using a deletion mutant of EV2038, and the epitope sequence of ITC52 reported in the past are shown. It is a graph which shows the result of having evaluated the neutralization activity of the anti- HCMV antibody concerning this invention.
- an antibody capable of specifically binding to gB glycoprotein of human cytomegalovirus (HCMV) and neutralizing its biological activity Antigen binding fragments are provided.
- an antibody or antigen-binding fragment thereof is provided that can specifically bind to a discontinuous epitope present in the AD1 region of the HCMV gB glycoprotein and neutralize the biological activity of the protein. .
- “Human cytomegalovirus (HCMV) gB glycoprotein” is one of the major glycoproteins constituting the envelope of HCMV, and is a virus particle. It is known to contribute to cell entry, cell fusion, and viral cell-to-cell infection.
- the amino acid sequence of the HCMV gB glycoprotein is obtained from the publicly available sequence database (Swiss-Prot), and the amino acid sequence of the protein of accession number: P06473 (SEQ ID NO: 137). ) Is available.
- AD1 region of gB glycoprotein of human cytomegalovirus (HCMV)” or “HCMV gB glycoprotein AD1 region” is a region consisting of consecutive amino acid residues at positions 552 to 635 in the amino acid sequence of HCMV gB glycoprotein. (Wagner et al., Journal of Virology, Vol. 66, No. 9, Sept. 1992, p.5290-5297).
- epipe is used in the meaning commonly used in the art, and means a small partial structure of an antigen molecule as a partner to which an antibody binds (Iwanami Biological Encyclopedia 4th Edition (1996). First year of printing))).
- the discontinuous epitope present in the AD1 region is an amino acid sequence consisting of consecutive amino acid residues at positions 549 to 580 of the human cytomegalovirus (HCMV) gB glycoprotein ( SEQ ID NO: 23) and an amino acid sequence consisting of consecutive amino acid residues at positions 596 to 640 (SEQ ID NO: 24). More specifically, the discontinuous epitope consists of the amino acid sequence of SEQ ID NO: 25, the amino acid sequence of SEQ ID NO: 26, and the amino acid sequence of SEQ ID NO: 27.
- HCMV human cytomegalovirus
- the antibody or antigen-binding fragment thereof of the present invention in one embodiment thereof, (a) a heavy chain (H chain) comprising the amino acid sequence of SEQ ID NO: 2 or 6, and (b) containing a light chain (L chain) comprising the amino acid sequence of SEQ ID NO: 4 or 8, wherein this antibody or antigen-binding fragment specifically binds to gB glycoprotein of human cytomegalovirus and its biological activity Can be neutralized.
- an antibody of the present invention or an antigen-binding fragment thereof can also be (a) a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 10, and (b) contains a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 12, and can specifically bind to human cytomegalovirus gB glycoprotein and neutralize its biological activity.
- HCVR heavy chain variable region
- LCVR light chain variable region
- the antibody or antigen-binding fragment thereof of the present invention further comprises (I) the amino acid sequences of CDR (Complementarity Determining Region) 1, CDR2, and CDR3 of the variable region of the heavy chain, (a) the amino acid sequence of SEQ ID NO: 13, (b) the amino acid sequence of SEQ ID NO: 14, and (c) the amino acid sequence of SEQ ID NO: 15, Containing (Ii) the amino acid sequences of CDR1, CDR2, and CDR3 of the variable region of the light chain, (a) the amino acid sequence of SEQ ID NO: 16, (b) the amino acid sequence of SEQ ID NO: 17, and (c) the amino acid sequence of SEQ ID NO: 18, Can specifically bind to the gB glycoprotein of human cytomegalovirus and neutralize its biological activity.
- CDR Complementarity Determining Region
- the antibody or antigen-binding fragment thereof of the present invention also has a function of the above-mentioned antibody or antigen-binding fragment that can specifically bind to the gB glycoprotein of human cytomegalovirus and neutralize its biological activity.
- Equivalents are also included, for example, (a) in the amino acid sequence of SEQ ID NO: 2 or 6, an amino acid sequence having a deletion, substitution, insertion, addition of any one to several amino acid residues, or a combination of any two or more thereof, or a sequence A heavy chain (H chain) represented by an amino acid sequence having 95% or more identity with the amino acid sequence of No. 2 or 6, and (b) 1 to several amino acid residues in the amino acid sequence of SEQ ID No.
- amino acid sequence having a deletion, substitution, insertion, addition, or mutation of any combination of any two or more thereof, or an amino acid sequence having 95% or more identity with the amino acid sequence of SEQ ID NO: 4 or 8 Contains light chain (L chain).
- functional equivalents of the above antibodies or antigen-binding fragments can also be (a) an amino acid sequence having a deletion, substitution, insertion, addition, or mutation of any combination of any two or more thereof in the amino acid sequence of SEQ ID NO: 10, or of SEQ ID NO: 10
- a heavy chain variable region (HCVR) comprising an amino acid sequence having 95% or more identity with the amino acid sequence
- deletion, substitution, insertion of one to several amino acid residues in the amino acid sequence of SEQ ID NO: 12 A light chain variable region (LCVR) comprising an amino acid sequence having an addition or a mutation of any combination of two or more thereof, or an amino acid sequence having 95% or more identity with the amino acid sequence of SEQ ID NO: 12 is contained.
- a functional equivalent of the antibody or antigen-binding fragment described above is further (I) (a) selected from the group consisting of amino acid sequences having deletions, substitutions, insertions, additions, or combinations of any two or more thereof in the amino acid sequence of SEQ ID NO: 13 Heavy chain CDR1, (b) selected from the group consisting of an amino acid sequence having a deletion, substitution, insertion, addition, or mutation of any combination of any two or more thereof in the amino acid sequence of SEQ ID NO: 14 (C) an amino acid sequence having a deletion, substitution, insertion, addition, or combination of any two or more of these in the amino acid sequence of SEQ ID NO: 15 And a heavy chain CDR3 selected from the group consisting of the amino acid sequence shown in SEQ ID NO: 22, and (ii) (a) selected from the group consisting of amino acid sequences having deletions, substitutions, insertions, additions, or combinations of any two or more of these in the amino acid sequence of SEQ ID NO: 16.
- Light chain CDR1 (b) selected from the group consisting of amino acid sequences having deletions, substitutions, insertions, additions, or combinations of any two or more of these in the amino acid sequence of SEQ ID NO: 17 (C) an amino acid sequence having a deletion, substitution, insertion, addition, or mutation of any combination of any two or more thereof in the amino acid sequence of SEQ ID NO: 18
- a light chain CDR3 selected from the group consisting of:
- the upper limit of the number of mutations in the amino acid sequence of the functional equivalent can be determined based on whether or not it can specifically bind to HCMV gB glycoprotein and neutralize its biological activity.
- the neutralizing activity of HCMV can be evaluated, for example, by the method described in Examples 9 and 10 described later.
- the evaluation of the ability to inhibit cell-to-cell infection can be performed, for example, by the method shown in Example 11.
- antibody as used herein is four polypeptide chains, two heavy (H) chains and two light (L) chains, interconnected by disulfide bonds. It shall refer to an immunoglobulin molecule consisting of things.
- the monoclonal antibody in the present invention is also composed of immunoglobulin molecules each containing two light chains (L chains) and heavy chains (H chains).
- Each heavy chain consists of three domains, the heavy chain variable region (sometimes referred to as “HCVR” or “V H ”) and the heavy chain constant region (the heavy chain constant region is “C H 1”). , “C H 2” and “C H 3” (generic name: C H )).
- Each L chain consists of an L chain variable region (sometimes referred to as “LCVR” or “V L ”) and an L chain constant region (the L chain constant region is referred to as “C L ”). May be).
- HCVR and LCVR are particularly important in that they are involved in antibody binding specificity. Since antibodies interact with target antigens primarily through LCVR and HCVR amino acid residues, the amino acid sequences within the variable region are more different between individual antibodies than sequences outside the variable region. Furthermore, HCVR and LCVR can be further subdivided into a region called a framework region (FR) and a hypervariable region called a complementarity determining region (CDR) that are kept more constant between various antibodies. HCVR and LCVR are each composed of 3 CDRs and 4 FRs, which are arranged in the order FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from the amino terminus to the carboxy terminus.
- FR framework region
- CDR complementarity determining region
- antibody fragment refers to a fragment of one or more antibodies capable of specifically binding to an antigen (eg, HCMV).
- the fragment includes a peptide having a minimum amino acid sequence that specifically binds to an antigen.
- antigen-binding fragment also included in the “antigen-binding fragment” are single-chain antibodies (scFV), bispecific antigens, multispecific antigens and the like having variable regions and complementarity determining regions of antibodies that specifically bind to antigens.
- scFV single-chain antibodies
- bispecific antigens bispecific antigens
- multispecific antigens multispecific antigens and the like having variable regions and complementarity determining regions of antibodies that specifically bind to antigens.
- antibody or antigen-binding fragment is also simply referred to as “antibody”.
- Antibodies capable of neutralizing the biological activity of HCMV shall refer to antibodies that inhibit the biological activity of HCMV by binding to HCMV or HCMV-infected cells.
- the “biological activity of HCMV” typically includes, but is not limited to, the activity of HCMV causing the diseases exemplified in (a) to (e) below.
- HCMV activity that induces various diseases caused by causes includes: (A) Various diseases such as interstitial pneumonia, retinitis, gastroenteritis, encephalitis due to reactivation of HCMV in immunodeficient states such as AIDS, cancer, organ transplantation, bone marrow transplantation, and hemodialysis; (B) congenital CMV infection caused by HCMV infection spreading from pregnant woman to fetus; (C) A miscarriage, stillbirth, or late birth death caused by the congenital CMV infection; (D) low birth weight, hepatosplenomegaly, jaundice, thrombocytopenic purpura, microcephaly, mental developmental disorder, delayed intellectual development, chorioretinitis and hearing impairment when not dying due to the congenital CMV infection; (E) Abnormal hepatic function, interstitial pneumonia, mononucleosis, etc. caused by HCMV infection in newborns and infants (Non-Patent Documents 3, 4, and 5).
- HCMV disease caused by HCMV
- a disease in which the biological activity of HCMV causes a disease is a disease in which the symptoms and / or progression of the disease is expected to be alleviated by inhibiting the biological activity of HCMV.
- diseases can be alleviated or cured using, for example, the anti-HCMV antibodies described above. Specifically, by increasing the concentration of anti-HCMV antibody in the biological fluid of the subject suffering from the disease (eg, increasing the concentration of anti-HCMV antibody in the serum or plasma of the subject, synovial fluid) The above diseases can be proved.
- the terms “inhibitory effect”, “inhibition”, “suppression”, “can inhibit” and the like refer to biological activity attributable to an antigen (HCMV) of about 5-100%, preferably 10 -100%, more preferably 20-100%, more preferably 30-100%, more preferably 40-100%, more preferably 50-100%, more preferably 60-100%, more preferably 70-100. %, More preferably 80 to 100%.
- HCMV antigen
- variable region sequence derived from a specific naturally occurring antibody or the sequence of the CDR portion is a different antibody having different properties.
- an expression vector that contains an invariant region or framework sequence derived from it the recombinant antibody that mimics the properties of a particular naturally occurring antibody can be expressed. Therefore, it is not necessary to obtain the entire sequence of a particular antibody when recreating an intact recombinant antibody having binding properties similar to those of the original antibody.
- the variable region region or CDR portion sequences of the antibody heavy and light chains may be sufficient for this purpose.
- SEQ ID NOs: 13, 14, and 15 are amino acid sequences corresponding to heavy chain CDR1, CDR2, and CDR3, respectively.
- SEQ ID NOs: 16, 17, and 18 are amino acid sequences corresponding to light chain CDR1, CDR2, and CDR3, respectively. Accordingly, preferred antibodies of the invention correspond to SEQ ID NOs: 13, 14, 15, 16, 17, and 18 corresponding to the heavy chain CDR1, CDR2, and CDR3 and the light chain CDR1, CDR2, and CDR3, respectively. Is the case.
- SEQ ID NOs: 13, 14, 15, 16, 17, and 18 are the heavy chain CDR1, CDR2, and CDR3, respectively, and It is not necessary to correspond to the light chain CDR1, CDR2 and CDR3.
- the heavy chain CDR-3 may be an amino acid sequence selected from the amino acid sequence group represented by SEQ ID NO: 22.
- one to several CDR sequences (specifically, one in the amino acid sequence selected from each group of SEQ ID NOs: 13, 14, 15, 16, 17, and 18) -9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, or 1) deletion of amino acid residues, It may be an amino acid sequence having a substitution, insertion, addition, or any combination of two or more of these mutations.
- the amino acid sequence other than the CDR is not particularly limited, and so-called CDR-grafted antibodies in which the amino acid sequence other than the CDR is derived from other antibodies, particularly other types of antibodies, are also included in the antibody of the present invention.
- antibodies whose amino acid sequences other than CDRs are also human-derived are preferable, but deletion of one to several amino acid residues (specific numbers are the same as above) in the framework region (FR) as necessary. , Substitutions, insertions, additions, or combinations of any two or more of these may be present.
- Known methods can be used for the production of these antibodies (Riechmann L, et al., Reshaping human antibodies for therapy. Nature, 332: 323-327, 1988). In the present invention, of course, fully human antibodies are preferred.
- amino acid sequence of the protein of the present invention one or more amino acid residues are deleted, substituted, inserted, added, or any combination of two or more thereof is any one or more amino acids in the same sequence It means that there is a deletion, substitution, insertion or addition of one or more amino acid residues at a position in the sequence, and two or more of deletion, substitution, insertion and addition may occur simultaneously.
- amino acids constituting natural proteins can be grouped according to the characteristics of their side chains.
- amino acids having similar characteristics include aromatic amino acids (tyrosine, phenylalanine, tryptophan), bases Amino acids (lysine, arginine, histidine), acidic amino acids (aspartic acid, glutamic acid), neutral amino acids (serine, threonine, asparagine, glutamine), amino acids having a hydrocarbon chain (alanine, valine, leucine, isoleucine, proline), And other groups (glycine, methionine, cysteine).
- amino acid residues that can be substituted with each other including non-natural amino acids include the following groups, and amino acid residues contained in the same group can be substituted with each other.
- Group A leucine, isoleucine, norleucine, valine, norvaline, alanine, 2-aminobutanoic acid, methionine, o-methylserine, t-butylglycine, t-butylalanine, cyclohexylalanine;
- Group B aspartic acid, glutamic acid, isoaspartic acid , Isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid;
- group C asparagine, glutamine;
- group D lysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid;
- group E Proline, 3-hydroxyproline, 4-hydroxyproline;
- Group F serine, threonine, homoserine;
- Group G phenylalanine, tyrosine, tryptophan.
- more preferred antibodies are: (a) the amino acid sequence of SEQ ID NO: 10; 1 to several (specifically, 1 to 9, 1 to 8, 1 to 7) of the amino acid sequence of SEQ ID NO: 10; 1-6, 1-5, 1-4, 1-3, 1-2, or 1) amino acid residue deletion, substitution, insertion, addition, or any two of these An amino acid sequence having two or more combinations of mutations; or 95% or more (preferably 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more) of the amino acid sequence of SEQ ID NO: 10 (B) the amino acid sequence of SEQ ID NO: 12; 1 to several amino acids in the amino acid sequence of SEQ ID NO: 12 (specific numbers are the same as above) Residue deletion, substitution, insertion, addition, or these A light chain variable region represented by an amino acid sequence having at least two combinations of mutations; or an amino acid sequence having 95% or more identity (specific% is the same as described above) with the amino acid sequence of SEQ ID NO
- more preferred antibodies include (a) a heavy chain variable region (HCVR) represented by the amino acid sequence of SEQ ID NO: 10 and (b) a light chain variable region (LCVR) represented by the amino acid sequence of SEQ ID NO: 12. contains.
- HCVR heavy chain variable region
- LCVR light chain variable region
- further preferred antibodies are: (a) amino acid sequence of SEQ ID NO: 6; deletion or substitution of 1 to several amino acid residues (specific numbers are the same as above) in the amino acid sequence of SEQ ID NO: 6 , Insertion, addition, or an amino acid sequence having a mutation of any combination of two or more thereof; or an amino acid sequence having 95% or more identity (specific% is the same as above) with the amino acid sequence of SEQ ID NO: 6 And (b) the amino acid sequence of SEQ ID NO: 8; deletion of one to several amino acid residues (specific numbers are the same as above) in the amino acid sequence of SEQ ID NO: 8 , Substitution, insertion, addition, or an amino acid sequence having a mutation of any combination of two or more thereof; or 95% or more (specific% is the same as above) with the amino acid sequence of SEQ ID NO: 8 amino Containing a light chain (L chain) of SEQ.
- the most preferred antibody in the present invention is a fully human monoclonal antibody containing a heavy chain (H chain) represented by the amino acid sequence of SEQ ID NO: 6 and a light chain (L chain) represented by the amino acid sequence of SEQ ID NO: 8. .
- a preferred antibody class (subclass) in the present invention is IgG1 ( ⁇ ).
- the above-described anti-HCMV antibody or antigen-binding fragment thereof according to the present invention specifically binds to HCMV causing various diseases, neutralizes its biological activity, and is more neutralized than conventional anti-HCMV antibodies. It has the function.
- “specifically binds” means to recognize and bind to a predetermined antigen.
- the dissociation constant (Kd value) of the antibody of the present invention from HCMV is preferably 1 ⁇ 10 ⁇ 7 M or less, more preferably 1 ⁇ 10 ⁇ 8 M or less, and further preferably Is 1 ⁇ 10 ⁇ 9 M or less, and most preferably 1 ⁇ 10 ⁇ 10 M or less.
- a known method can be used to measure the dissociation constant between the antibody and HCMV.
- it can be measured by a protein interaction analyzer such as BIACORET 100 (registered trademark) using an anti-HCMV antibody immobilized on a chip.
- the neutralizing ability of the anti-HCMV antibody can be evaluated by examining the infection inhibition rate and the plaque formation inhibition rate by immunostaining. That is, when inoculating a cell culture system capable of infecting AD169 strain and Towne strain, which are representative strains of HCMV, with an anti-HCMV antibody at various concentrations for a certain period of time in advance, and then inoculating them into cells.
- the neutralization activity of anti-HCMV antibody is measured by measuring the number of HCMV-infected cells by immunostaining 24 hours after infection to determine the infection inhibition rate, or by obtaining the inhibition rate from the number of plaques formed 5 to 6 days after infection. can do.
- the anti-HCMV antibody or antigen-binding fragment thereof according to the present invention preferably has a neutralizing activity against AD169 strain of 1 ⁇ g / mL (about 7 nM) or less, more preferably 0.1 ⁇ g / mL (about 0.7 nM). Below, even more preferably 0.05 ⁇ g / mL (about 0.3 nM) or less, and most preferably about 0.03 ⁇ g / mL (about 0.2 nM) or less, about 50% of plaque formation inhibiting ability.
- the ability to inhibit intercellular infection is to evaluate the inhibitory effect of intercellular infection by culturing cells previously infected with HCMV for a certain period of time and then adding various concentrations of anti-HCMV antibodies to the cell culture system. I can do it.
- the anti-HCMV antibody or antigen-binding fragment thereof according to the present invention preferably has a final concentration of 2 ⁇ g / mL (about 13 nM) or less, more preferably 0.5 ⁇ g / mL (about 3 nM) or less, and even more preferably 0. It has an ability to inhibit intercellular infection of 50% or more at 2 ⁇ g / mL (about 0.13 nM) or less.
- the antibody of the present invention is a full-length antibody or an antigen-binding fragment thereof, the amino acid sequence of SEQ ID NO: 6, 8, 10 or 12 indicating a variable region, or the SEQ ID NO indicating a complementarity determining region (CDR).
- CDR complementarity determining region
- the heavy and light chain signal sequences are cleaved during protein maturation and do not contribute to the properties of the final antibody, but to add missing sequences
- the cloned cDNA sequences are It can be combined with synthetic oligonucleotides by ligation or PCR amplification methods.
- the entire variable region can be synthesized as a set of short, overlapping oligonucleotides and combined in a PCR amplification method to create a fully artificial variable region clone.
- nucleic acid encoding an antibody or the like According to another embodiment of the present invention, an anti-HCMV monoclonal antibody or an antigen-binding fragment thereof that specifically binds to HCMV and can neutralize its biological activity is encoded.
- a nucleic acid encoding an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 13-18 and 22, and hybridizing with the nucleic acid under highly stringent conditions An isolated nucleic acid selected from soy nucleic acids is provided.
- the nucleic acid is DNA or RNA, more preferably DNA.
- a nucleic acid encoding an anti-HCMV monoclonal antibody or antigen-binding fragment thereof capable of binding to HCMV and neutralizing its biological activity comprising 2, 4, 6, 8, 10, 12, 13-18 and 22
- Isolated nucleic acids having a high identity with a nucleic acid encoding an amino acid sequence selected from the group are also included in the present invention.
- “having high identity” means sequence identity to the extent that it can hybridize to a given nucleic acid sequence under highly stringent conditions, for example, 60%, 70%, It means having 80%, 90%, or 95% or more identity.
- “High stringent conditions” are, for example, 5 ⁇ SSC, 5 ⁇ Denhardt's solution, 0.5% SDS, 50% formamide, 50 ° C.
- nucleic acid examples include a nucleic acid encoding any one of the amino acid sequences of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 13-18, and 22, for example, 70% or more , 80% or more, 90% or more, 95% or more, 97% or more, or 99% or more nucleic acid having the identity.
- the identity of the base sequence can be determined using the above-described identity search algorithm (Proc. Natl. Acad. Sci. USA 872264-2268, 1990; Proc Natl Acad Sci USA 90: 5873, 1993) .
- the nucleic acid preferred in the present invention is DNA encoding both the amino acid sequences of SEQ ID NOs: 10 and 12, and more preferably DNA encoding both the amino acid sequences of SEQ ID NOs: 6 and 8. Even more preferred nucleic acids are DNAs that encode both the amino acid sequences of SEQ ID NOs: 2 and 4. Even more preferred nucleic acids are nucleic acids comprising both nucleic acids of SEQ ID NOs: 5 and 7, and even more preferred nucleic acids are nucleic acids comprising both nucleic acids of SEQ ID NOs: 1 and 3.
- the present invention also relates to a vector incorporating the nucleic acid, a host cell into which the vector has been introduced, and an antibody production method using these.
- the antibody of the present invention can also be prepared as a recombinant human antibody using a known method (see Nature, 312: 643, 1984, Nature, 321: 522, 1986, etc.).
- the antibody of the present invention can be produced by culturing host cells into which the vector of the present invention has been introduced, and purifying the produced antibody from the culture supernatant or the like.
- an expression vector for animal cells containing a gene encoding a human antibody C H and / or a human antibody C L prepared from cDNA encoding V H and V L from the same cell or another human cell. It can be produced by constructing a human antibody expression vector by inserting each vector, introducing it into an animal cell and expressing it.
- the vector into which the nucleic acid encoding the V H or V L of the antibody of the present invention is not necessarily limited, but a vector or a high expression vector that is generally used for expression of protein genes and the like and is particularly suitable for expression of antibody genes is preferred. . Suitable examples include vectors containing the EF promoter and / or CMV enhancer. In addition, expression vectors that normally incorporate nucleic acids encoding VH or VL are prepared and cotransfected into host cells, but they may be incorporated into a single expression vector.
- the host cell into which the expression vector is introduced is not necessarily limited, but a cell that is widely used for the expression of protein genes and the like and is particularly suitable for the expression of antibody genes is preferred. Examples include bacteria (such as E. coli), actinomycetes, yeast, insect cells (such as SF9), and mammalian cells (such as COS-1, CHO, and myeloma cells).
- a recombinant animal cell line that stably produces the antibody for example, a CHO cell line is generally used.
- Known methods can be used to generate, clone, and amplify and screen such recombinant cell lines (eg, Omasa T .: J. Biosci. Bioeng.,. 94, 600-605). , See 2002 etc.).
- the present invention includes an antigen-binding fragment of the antibody of the present invention in addition to an antibody composed of two heavy chains and two light chains.
- the antigen-binding fragment include Fab (fragment of antigen binding), Fab ′, and F (ab ′) 2.
- Fab fragment of antigen binding
- Fab ′ fragment of antigen binding
- F (ab ′) 2 a single chain antibody
- peptides containing active fragments of antibodies include CDR-containing peptides.
- These can be produced by a known method such as a method of treating the antibody of the present invention with an appropriate proteolytic enzyme or a gene recombination technique. Purification of the antibody can be performed using a known purification means such as salting out, gel filtration, ion exchange chromatography or affinity chromatography.
- the diversified scFv (which has been developed by artificially shuffling the V H and V L genes by the phage display antibody technology, which uses genetic engineering technology to express recombinant antibodies (recombinant antibodies) on the phage surface.
- a specific antibody can also be obtained by expressing a single chain fragment of variable region antibody as a phage fusion protein.
- This technique is highly evaluated as a humanized antibody production technique that can avoid immunity and is replaced with a cell fusion method.
- any specific antibody or antigen-binding fragment thereof prepared by referring to the amino acid sequences of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 13-18 and 22 in the present specification can be used. It belongs to the technical scope of the invention.
- an antibody Obtained by applying a potellent technology that has been developed in recent years to significantly improve the ADCC activity of an antibody by modifying the sugar chain portion of the antibody. al, Clin. Cancer Res., 10, 6248-6255 (2004)) or an antibody obtained by applying the Complement technology for improving CDC activity to the antibody of the present invention (Kanda S., et al. al, Glycobiology, 17, 104-118 (2007)) also belongs to the technical scope of the present invention.
- polyclonal antibodies and monoclonal antibodies are usually obtained using laboratory animals such as mice, rabbits, goats, etc., but the antibodies thus obtained were used. Since it has a sequence characteristic to animal species, if it is administered to humans as it is, it is recognized as a foreign substance by the human immune system, and a human anti-animal antibody response may occur (that is, an antibody of an antibody is produced).
- the anti-HCMV monoclonal antibody or antigen-binding fragment thereof according to the present invention can be obtained from blood-derived antibody-producing cells such as healthy persons, and is a fully human antibody. Even if this fully human antibody is administered to the human body as an antibody drug, it is considered that it has no immunogenicity and no immune reaction is observed.
- the anti-HCMV monoclonal antibody of the present invention has a higher neutralizing ability than conventional anti-HCMV monoclonal antibodies, the same therapeutic effect can be expected with a smaller dose.
- the anti-HCMV monoclonal antibody and antigen-binding fragment thereof according to the present invention were obtained from the culture supernatant of an antibody-producing cell clone by separating the cell clone producing the antibody from blood of a healthy person through various steps.
- the antibody can be obtained by affinity purification.
- Isolation of fully human antibody-producing cell clones against HCMV B lymphocytes are isolated from the blood of a healthy person, and the proliferation of the B lymphocytes is induced.
- Methods for inducing proliferation are known per se, for example, a transform method (D. Kozbor) using “Epstein-Barr virus” (hereinafter referred to as EBV), which is an inducer of cancer. Et al.). That is, the B lymphocytes are infected with EBV to induce proliferation, and the proliferated cells are used as an antibody-producing cell library.
- the method of recovering monoclonal antibody from cells induced to proliferate can be carried out by well-known methods commonly used in the production of monoclonal antibodies.
- a lymphocyte clone that produces an antibody that binds to HCMV is selected from the antibody-producing cell library, and the antibody is removed from the culture supernatant. That is, a cell population (clone) that produces an antibody that binds to HCMV is selected from the antibody-producing cell library by a limiting dilution method.
- ELISA using HCMV-derived antigen and labeled mouse anti-human IgG antibody is preferably employed. By culturing the selected antibody-positive cell population and repeating the screening, a cell population (clone) that produces only the target antibody can be obtained.
- selected cells can be grown in roller bottles, 2 liter spinner flasks, or other culture systems.
- the obtained culture supernatant is filtered, concentrated, and then subjected to affinity chromatography using protein A or protein G-Sepharose (GE Healthcare) to purify the protein.
- the buffer can be exchanged for PBS and the concentration can be determined by OD 280 or preferably by nephelometer analysis.
- the isotype can be determined by a method specific to the isotype antigen.
- the anti-HCMV antibody thus obtained is a fully human antibody prepared from B lymphocytes sensitized in the human body, the possibility of an immune reaction to the antibody is low.
- Another feature of the production of antibody-producing cell clones is the use of an EB virus that has the activity of inducing proliferation by infecting B lymphocytes.
- the advantage of the EB virus method is that a natural antibody produced in the human body can be produced and an antibody with high affinity can be obtained.
- human antibodies against HCMV have been found to be about 10-100 times more affinity than antibodies made by artificially immunizing mice.
- a population of B lymphocytes proliferated by EB virus infection becomes a library of antibody-producing cells.
- a specific antibody-producing cell clone can be isolated from this library to obtain a human antibody.
- composition containing antibody provides a method for preventing or preventing a disease associated with human cytomegalovirus (HCMV) comprising the antibody or antigen-binding portion thereof and a pharmaceutically acceptable carrier.
- HCMV human cytomegalovirus
- a disease caused by HCMV is a disease in which inhibition of HCMV activity is expected to alleviate the symptoms and / or progression of the disease.
- the term “disease involving HCMV” means that a subject suffering from the disease having HCMV is responsible for the pathophysiology of the disease or aggravates the disease. Diseases and other illnesses that have been shown or suspected to be causative are to be included.
- the anti-HCMV antibody or antigen-binding fragment thereof according to the present invention has a high neutralizing ability against HCMV, various diseases caused by HCMV such as (a) AIDS, cancer, Various diseases such as interstitial pneumonia, retinitis, gastroenteritis, encephalitis due to reactivation of HCMV in an immunodeficient state such as after organ transplantation, bone marrow transplantation, and after hemodialysis, and (b) HCMV from pregnant woman to fetus Congenital CMV infection caused by the spread of infection, (c) miscarriage, stillbirth, short-term death caused by the congenital CMV infection, (d) low birth in the case of no death due to the congenital CMV infection Body weight, hepatosplenomegaly, jaundice, thrombocytopenic purpura, microcephaly, mental developmental disorder, delayed intellectual development, chorioretinitis and hearing impairment, (e) due to HCMV infection in neonates and infants
- pharmaceutically acceptable carrier includes any and all physiologically compatible solvents, dispersion media, coatings, isotonic and absorption delaying agents and the like.
- pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like, as well as combinations thereof.
- the composition preferably contains a pH adjuster or isotonic agent such as sugar, polyalcohol such as mannitol or sorbitol, or sodium chloride.
- Pharmaceutically acceptable carriers can additionally contain minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives, buffering agents, stabilizing agents and the like that increase the preservability or effectiveness of the antibody or antibody portion.
- compositions of the present invention can be made into various dosage forms.
- Such compositions include, for example, liquids, semi-solids such as solutions (eg, injectable and infusible solutions) and dispersions, suspensions, tablets, capsules, troches, pills, powders, liposomes, suppositories, etc.
- Solid dosage forms are included. The preferred form depends on the intended mode of administration and therapeutic application. Generally preferred compositions are in the form of injectable or infusible solutions, such as compositions similar to those used to passively immunize humans with other antibodies.
- Preferred dosage forms are parenteral (eg, intravenous, subcutaneous, intraperitoneal, intramuscular).
- the antibody is administered by intravenous infusion or intravenous injection.
- the antibody is administered by intramuscular or subcutaneous injection.
- the antibodies and antibody fragments of the present invention can be incorporated into pharmaceutical compositions suitable for parenteral administration.
- the antibody or antibody portion is preferably prepared as an injectable preparation containing 0.1 to 250 mg / mL of antibody when a single type is used.
- an injectable preparation containing 0.001 to 100 mg / mL of antibody.
- the mixing ratio of the plurality of types of antibodies can be set as appropriate.
- the injectable preparation can be constituted by dissolving the active ingredient in a liquid or freeze-drying the active ingredient in a flint or amber vial, ampoule or prefilled syringe.
- the buffer can be L-histidine (1-50 mM) at pH 5.0-7.0 (optimally pH 6.0), and 5-10 mM L-histidine, optimally.
- Other suitable buffering agents include, but are not limited to, sodium succinate, sodium citrate, sodium phosphate, or potassium phosphate.
- Sodium chloride can be used to change the osmotic pressure of a 0-300 mM concentration solution (150 mM, optimal for liquid dosage forms).
- the lyophilized dosage form can contain a cryoprotectant, primarily 0-10% (optimally 0.5-5.0%) sucrose.
- suitable cryoprotectants include mannitol, trehalose and lactose.
- the lyophilized dosage form can contain a bulking agent, primarily 1-10% mannitol (2-4% when optimal).
- stabilizers primarily 1-50 mM (optimally 5-10 mM) L-methionine can be used.
- stabilizers include glycine, arginine, polysorbate 80, and the like, and in the case of polysorbate 80 can include 0-0.05% (optimally 0.005-0.01%).
- surfactants include, but are not limited to, polysorbate 20 and BRIJ surfactant.
- the pharmaceutical composition generally must be sterile or stable under the conditions of manufacture and storage.
- the composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration.
- Sterile injectable solutions are prepared by mixing the required amount of active compound (ie antibody or antibody portion) in a suitable solvent with one or a combination of the above components, if necessary, followed by filter sterilization. It can be prepared by doing.
- dispersions are prepared by mixing the active compound with a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
- a sterile powder formulation for the preparation of a sterile injectable solution the preferred method of preparation is freeze vacuum drying and spray drying of the sterile filtered solution as previously described, thereby adding to the active ingredient powder, A composition containing any other desired ingredients is obtained.
- the proper fluidity of the solution can be achieved, for example, by using a coating such as lecithin, by maintaining the required particle size in the case of dispersions, and by using surfactants. Can be maintained.
- Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts or gelatin.
- an antibody or antibody portion of the invention is formulated together with one or more other therapeutic agents useful for treating a disease caused by HCMV, or such other therapeutic agents Administer at the same time.
- an anti-HCMV antibody or antibody portion of the invention is formulated together with one or more other antibodies that bind to other targets (eg, antibodies that bind to other binding sites of HCMV), or Can be administered simultaneously with other antibodies.
- one or more antibodies of the present invention can be used in combination of two or more of the aforementioned therapeutic agents. Such combination therapy can advantageously utilize lower doses of the administered therapeutic agent, thus avoiding the toxicities or complications that may be associated with various single therapies.
- SEQ ID NO: 1 This represents a nucleotide sequence encoding the heavy chain of an antibody against the AD1 region of the HCMV gB glycoprotein (hereinafter “anti-AD1 antibody”) (EV2038), including a signal sequence.
- SEQ ID NO: 2 The amino acid sequence of the heavy chain of the anti-AD1 antibody (EV2038) including the signal sequence.
- SEQ ID NO: 3 The nucleotide sequence encoding the light chain of the anti-AD1 antibody (EV2038), including the signal sequence.
- SEQ ID NO: 4 It represents the amino acid sequence of the L chain of the anti-AD1 antibody (EV2038) including the signal sequence.
- SEQ ID NO: 5 This represents the nucleotide sequence encoding the heavy chain of the anti-AD1 antibody (EV2038) without the signal sequence.
- SEQ ID NO: 6 The amino acid sequence of the heavy chain of the anti-AD1 antibody (EV2038) does not include a signal sequence.
- SEQ ID NO: 7 This represents the nucleotide sequence encoding the light chain of the anti-AD1 antibody (EV2038) without the signal sequence.
- SEQ ID NO: 8 The amino acid sequence of the L chain of the anti-AD1 antibody (EV2038) does not include a signal sequence.
- SEQ ID NO: 9 This represents the nucleotide sequence encoding the heavy chain variable region of the anti-AD1 antibody (EV2038).
- SEQ ID NO: 10 1 represents the amino acid sequence of the heavy chain variable region of the anti-AD1 antibody (EV2038).
- SEQ ID NO: 11 The nucleotide sequence encoding the light chain variable region of the anti-AD1 antibody (EV2038).
- SEQ ID NO: 12 1 represents the amino acid sequence of the light chain variable region of the anti-AD1 antibody (EV2038).
- SEQ ID NO: 13 1 represents the amino acid sequence of the heavy chain CDR1 of the anti-AD1 antibody (EV2038).
- SEQ ID NO: 14 1 represents the amino acid sequence of the heavy chain CDR2 of the anti-AD1 antibody (EV2038).
- SEQ ID NO: 15 1 represents the amino acid sequence of the heavy chain CDR3 of the anti-AD1 antibody (EV2038).
- SEQ ID NO: 16 1 represents the amino acid sequence of the light chain CDR1 of the anti-AD1 antibody (EV2038).
- SEQ ID NO: 17 1 represents the amino acid sequence of the L chain CDR2 of the anti-AD1 antibody (EV2038).
- SEQ ID NO: 18 1 represents the amino acid sequence of the light chain CDR3 of the anti-AD1 antibody (EV2038).
- SEQ ID NO: 19 The nucleotide sequence of 38 Hind-S primer used when producing EV2038 CDR-H3 variant in an Example is represented.
- SEQ ID NO: 20 The nucleotide sequence of 38 Not-A primer used when producing CDR-H3 variant of EV2038 in the Examples is shown.
- SEQ ID NO: 21 In the Examples, the nucleotide sequence of the primer for confirming the base sequence used in preparing the CDR20H variant of EV2038 is shown.
- SEQ ID NO: 22 2 represents a consensus amino acid sequence in the amino acid sequence of CDR-H3 of anti-AD1 antibody.
- SEQ ID NO: 23 The amino acid sequence consisting of amino acid residues from position 549 to position 580 of the HCMV gB glycoprotein AD1 region identified as the region where the epitope is present by the deletion mutation method shown in the Examples.
- SEQ ID NO: 24 The amino acid sequence consisting of amino acid residues from position 596 to position 640 of the HCMV gB glycoprotein AD1 region identified as the region where the epitope is present by the deletion mutation method shown in the Examples.
- SEQ ID NO: 25 The amino acid sequence consisting of amino acid residues from position 549 to position 560 of the HCMV gB glycoprotein AD1 region identified as an epitope region by the peptide array method shown in the Examples.
- SEQ ID NO: 26 The amino acid sequence consisting of amino acid residues from positions 569 to 576 of the HCMV gB glycoprotein AD1 region identified as the epitope region by the peptide array method shown in the Examples.
- SEQ ID NO: 27 The amino acid sequence consisting of amino acid residues from 625 to 632 in the HCMV gB glycoprotein AD1 region identified as an epitope region by the peptide array method shown in the Examples.
- SEQ ID NO: 28 This represents the amino acid sequence of a mutant in which valine (V) at position 117 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with lysine (K).
- SEQ ID NO: 29 The amino acid sequence of the mutant in which threonine (T) at position 118 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with tryptophan (W) is shown.
- SEQ ID NO: 30 The amino acid sequence of the variant which substituted arginine (R) of the 119th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by valine (V) is represented.
- SEQ ID NO: 31 The amino acid sequence of the variant which substituted aspartic acid (D) of the 120th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by isoleucine (I) is represented.
- SEQ ID NO: 32 3 shows the amino acid sequence of a mutant in which leucine (L) at position 121 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with glutamic acid (E).
- SEQ ID NO: 33 The amino acid sequence of the variant which substituted the glutamic acid (E) of the 122nd position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by leucine (L) is represented.
- SEQ ID NO: 34 3 represents the amino acid sequence of a mutant in which tryptophan (W) at position 123 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is replaced with threonine (T).
- SEQ ID NO: 35 This represents the amino acid sequence of a mutant in which isoleucine (I) at position 124 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with aspartic acid (D).
- SEQ ID NO: 36 The amino acid sequence of the variant which substituted the 125th proline (P) in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by arginine (R) is represented.
- SEQ ID NO: 37 The amino acid sequence of the variant which substituted the glycine (G) of 126th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by phenylalanine (F) is represented.
- SEQ ID NO: 38 3 shows the amino acid sequence of a mutant in which aspartic acid (D) at position 127 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is replaced with isoleucine (I).
- SEQ ID NO: 39 The amino acid sequence of the mutant in which tyrosine (Y) at position 128 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with asparagine (N) is shown.
- SEQ ID NO: 40 The amino acid sequence of the variant which substituted asparagine (N) the tyrosine (Y) of the 129th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention is represented.
- SEQ ID NO: 41 The amino acid sequence of the variant which substituted the methionine (M) of the 130th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by glutamine (Q) is represented.
- SEQ ID NO: 42 The amino acid sequence of the variant which substituted aspartic acid (D) of the 131st position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by isoleucine (I) is represented.
- SEQ ID NO: 43 This represents the amino acid sequence of the mutant in which valine (V) at position 132 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with lysine (K).
- SEQ ID NO: 44 The amino acid sequence of the variant which substituted the leucine (L) of the 121st position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by isoleucine (I) is represented.
- SEQ ID NO: 45 3 shows the amino acid sequence of a mutant in which leucine (L) at position 121 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with valine (V).
- SEQ ID NO: 46 3 shows the amino acid sequence of a mutant in which leucine (L) at position 121 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with alanine (A).
- SEQ ID NO: 47 The amino acid sequence of the variant which substituted the leucine (L) of the 121st position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by phenylalanine (F) is represented.
- SEQ ID NO: 48 3 shows the amino acid sequence of a mutant in which leucine (L) at position 121 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is replaced with proline (P).
- SEQ ID NO: 49 3 represents the amino acid sequence of a mutant in which tryptophan (W) at position 123 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with tyrosine (Y).
- SEQ ID NO: 50 This represents the amino acid sequence of a mutant in which tryptophan (W) at position 123 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with phenylalanine (F).
- SEQ ID NO: 51 This represents the amino acid sequence of a mutant in which tryptophan (W) at position 123 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is replaced with proline (P).
- SEQ ID NO: 52 3 shows the amino acid sequence of a mutant in which tryptophan (W) at position 123 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is replaced with leucine (L).
- SEQ ID NO: 53 3 represents the amino acid sequence of a mutant in which tryptophan (W) at position 123 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is replaced with isoleucine (I).
- SEQ ID NO: 54 This represents the amino acid sequence of a variant in which isoleucine (I) at position 124 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is replaced with leucine (L).
- SEQ ID NO: 55 This represents the amino acid sequence of a mutant in which isoleucine (I) at position 124 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with methionine (M).
- SEQ ID NO: 56 This represents the amino acid sequence of a mutant in which isoleucine (I) at position 124 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with proline (P).
- SEQ ID NO: 57 This represents the amino acid sequence of a mutant in which isoleucine (I) at position 124 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with valine (V).
- SEQ ID NO: 58 This represents the amino acid sequence of a variant in which isoleucine (I) at position 124 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with alanine (A).
- SEQ ID NO: 59 The amino acid sequence of the variant which substituted glycine (G) of the 126th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by proline (P) is represented.
- SEQ ID NO: 60 The amino acid sequence of the variant which substituted the glycine (G) of 126th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by the alanine (A) is represented.
- SEQ ID NO: 61 This represents the amino acid sequence of a mutant in which glycine (G) at position 126 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with serine (S).
- SEQ ID NO: 62 The amino acid sequence of the variant which substituted glycine (G) of the 126th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by asparagine (N) is represented.
- SEQ ID NO: 63 3 represents the amino acid sequence of a mutant in which glycine (G) at position 126 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is replaced with threonine (T).
- SEQ ID NO: 64 The amino acid sequence of the variant which substituted the 125th proline (P) in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by glycine (G) is represented.
- SEQ ID NO: 65 This represents the amino acid sequence of a mutant in which proline (P) at position 125 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is replaced with isoleucine (I).
- SEQ ID NO: 66 3 represents the amino acid sequence of a mutant in which proline (P) at position 125 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with alanine (A).
- SEQ ID NO: 67 3 represents the amino acid sequence of a mutant in which proline (P) at position 125 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is replaced with leucine (L).
- SEQ ID NO: 68 The amino acid sequence of the variant which substituted the 125th proline (P) in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by valine (V) is represented.
- SEQ ID NO: 69 The amino acid sequence of the variant which substituted the 125th proline (P) in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by serine (S) is represented.
- SEQ ID NO: 70 The amino acid sequence of the variant which substituted the 125th proline (P) in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention with threonine (T).
- SEQ ID NO: 71 The amino acid sequence of the variant which substituted asparagine (N) the 125th position proline (P) in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention.
- SEQ ID NO: 72 The amino acid sequence of the variant which substituted the proline (P) of 125th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by glutamine (Q) is represented.
- SEQ ID NO: 73 The amino acid sequence of the variant which substituted aspartic acid (D) the proline (P) of 125th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention is represented.
- SEQ ID NO: 74 The amino acid sequence of the variant which substituted the 125th proline (P) in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by glutamic acid (E) is represented.
- SEQ ID NO: 75 The amino acid sequence of the variant which substituted the 125th proline (P) in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by lysine (K) is represented.
- SEQ ID NO: 76 The amino acid sequence of the variant which substituted the 125th proline (P) in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by histidine (H) is represented.
- SEQ ID NO: 77 The amino acid sequence of the variant which substituted the 125th proline (P) in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by cysteine (C) is represented.
- SEQ ID NO: 78 This represents the amino acid sequence of a mutant in which the proline (P) at position 125 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with methionine (M).
- SEQ ID NO: 79 The amino acid sequence of the mutant in which proline (P) at position 125 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is replaced with tyrosine (Y).
- SEQ ID NO: 80 This represents the amino acid sequence of a mutant in which proline (P) at position 125 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with tryptophan (W).
- SEQ ID NO: 81 The amino acid sequence of the variant which substituted the 125th proline (P) in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by phenylalanine (F) is represented.
- SEQ ID NO: 82 3 represents the amino acid sequence of a mutant in which valine (V) at position 117 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with leucine (L).
- SEQ ID NO: 83 This represents the amino acid sequence of the mutant in which valine (V) at position 117 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is replaced with isoleucine (I).
- SEQ ID NO: 84 This represents the amino acid sequence of a mutant in which threonine (T) at position 118 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with serine (S).
- SEQ ID NO: 85 This represents the amino acid sequence of a mutant in which threonine (T) at position 118 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with lysine (K).
- SEQ ID NO: 86 This represents the amino acid sequence of a mutant in which arginine (R) at position 119 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with lysine (K).
- SEQ ID NO: 87 3 represents the amino acid sequence of a mutant in which arginine (R) at position 119 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is replaced with threonine (T).
- SEQ ID NO: 88 The amino acid sequence of the variant which substituted aspartic acid (D) of the 120th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by glutamic acid (E) is represented.
- SEQ ID NO: 89 The amino acid sequence of the variant which substituted aspartic acid (D) of the 120th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by the alanine (A) is represented.
- SEQ ID NO: 90 The amino acid sequence of the mutant in which glutamic acid (E) at position 122 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with aspartic acid (D) is shown.
- SEQ ID NO: 91 The amino acid sequence of the variant which substituted the glutamic acid (E) of the 122nd position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by the alanine (A) is represented.
- SEQ ID NO: 92 The amino acid sequence of the mutant in which the aspartic acid (D) at position 127 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with glutamic acid (E) is shown.
- SEQ ID NO: 93 The amino acid sequence of the variant which substituted the aspartic acid (D) of 127th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by the alanine (A) is represented.
- SEQ ID NO: 94 This represents the amino acid sequence of a mutant in which tyrosine (Y) at position 128 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with phenylalanine (F).
- SEQ ID NO: 95 The amino acid sequence of the mutant in which tyrosine (Y) at position 128 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with tryptophan (W) is shown.
- SEQ ID NO: 96 This represents the amino acid sequence of the mutant in which tyrosine (Y) at position 129 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with phenylalanine (F).
- SEQ ID NO: 97 This represents the amino acid sequence of a mutant in which tyrosine (Y) at position 129 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with tryptophan (W).
- SEQ ID NO: 98 The amino acid sequence of the variant which substituted the methionine (M) of the 130th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by phenylalanine (F) is represented.
- SEQ ID NO: 99 The amino acid sequence of the variant which substituted the methionine (M) of the 130th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by isoleucine (I) is represented.
- SEQ ID NO: 100 The amino acid sequence of the variant which substituted aspartic acid (D) of the 131st position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by glutamic acid (E) is represented.
- SEQ ID NO: 101 The amino acid sequence of the variant which substituted aspartic acid (D) of the 131st position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by the alanine (A) is represented.
- SEQ ID NO: 102 The amino acid sequence of the variant which substituted valine (V) of the 132nd position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by tyrosine (Y) is represented.
- SEQ ID NO: 103 3 represents the amino acid sequence of a mutant in which valine (V) at position 132 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention is substituted with serine (S).
- SEQ ID NO: 104 In the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention, an amino acid of a variant in which isoleucine (I) at position 124 is replaced with valine (V) and glycine (G) at position 126 is replaced with alanine (A) Represents an array.
- SEQ ID NO: 105 In the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention, an amino acid of a variant in which isoleucine (I) at position 124 is replaced with valine (V) and glycine (G) at position 126 is replaced with serine (S) Represents an array.
- leucine (L) at position 121 is isoleucine (I)
- tryptophan (W) at position 123 is tyrosine (Y)
- isoleucine at position 124 The amino acid sequence of the mutant in which I) is substituted with valine (V) and glycine (G) at position 126 with alanine (A).
- SEQ ID NO: 107 In the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention, leucine (L) at position 121 is isoleucine (I), tryptophan (W) at position 123 is tyrosine (Y), and isoleucine at position 124 ( The amino acid sequence of the mutant in which I) is replaced with valine (V) and glycine (G) at position 126 is replaced with serine (S). SEQ ID NO: 108 The amino acid sequence of the mutant which deleted the glutamic acid (E) at position 122 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention.
- SEQ ID NO: 109 The amino acid sequence of the mutant in which glutamic acid (E) is inserted between glycine (G) at position 126 and aspartic acid (D) at position 127 in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of the present invention.
- SEQ ID NO: 110 The amino acid sequence of the variant which substituted asparagine (N) of the 79th position in the amino acid sequence of the H chain of the anti-AD1 antibody (EV2038) of this invention by glutamine (Q) is represented.
- SEQ ID NO: 111 1 represents the amino acid sequence of the synthetic peptide (peptide 1 in Table 5) prepared and used in Example 8.
- SEQ ID NO: 112 The amino acid sequence of the synthetic peptide (peptide 2 in Table 5) prepared and used in Example 8 is shown.
- SEQ ID NO: 113 The amino acid sequence of the synthetic peptide produced and used in Example 8 (peptide 3 in Table 5) is shown.
- SEQ ID NO: 114 The amino acid sequence of the synthetic peptide produced and used in Example 8 (peptide 4 in Table 5) is shown.
- SEQ ID NO: 115 1 represents the amino acid sequence of the synthetic peptide (peptide 5 in Table 5) prepared and used in Example 8.
- SEQ ID NO: 116 1 represents the amino acid sequence of the synthetic peptide (peptide 6 in Table 5) prepared and used in Example 8.
- SEQ ID NO: 117 The amino acid sequence of the synthetic peptide (peptide 7 in Table 5) prepared and used in Example 8 is shown.
- SEQ ID NO: 118 1 represents the amino acid sequence of the synthetic peptide prepared and used in Example 8 (peptide 8 in Table 5).
- SEQ ID NO: 119 1 represents the amino acid sequence of the synthetic peptide (peptide 9 in Table 5) prepared and used in Example 8.
- SEQ ID NO: 120 The amino acid sequence of the synthetic peptide (peptide 10 in Table 5) prepared and used in Example 8 is shown.
- SEQ ID NO: 121 1 represents the amino acid sequence of the synthetic peptide (peptide 11 in Table 5) prepared and used in Example 8.
- SEQ ID NO: 122 The amino acid sequence of the synthetic peptide (peptide 12 in Table 5) prepared and used in Example 8 is shown.
- SEQ ID NO: 123 The amino acid sequence of the synthetic peptide produced and used in Example 8 (peptide 13 in Table 5) is shown.
- SEQ ID NO: 124 1 represents the amino acid sequence of the synthetic peptide produced and used in Example 8 (peptide 14 in Table 5).
- SEQ ID NO: 125 The amino acid sequence of the synthetic peptide (peptide 15 in Table 5) prepared and used in Example 8 is shown.
- SEQ ID NO: 126 1 represents the amino acid sequence of the synthetic peptide produced and used in Example 8 (peptide 16 in Table 5).
- SEQ ID NO: 127 The amino acid sequence of the synthetic peptide (peptide 17 in Table 5) prepared and used in Example 8 is shown.
- SEQ ID NO: 128 The amino acid sequence of the synthetic peptide produced and used in Example 8 (peptide 18 in Table 5) is shown.
- SEQ ID NO: 129 The amino acid sequence of the synthetic peptide produced and used in Example 8 (peptide 19 in Table 5) is shown.
- SEQ ID NO: 130 1 represents the amino acid sequence of the synthetic peptide prepared and used in Example 8 (peptide 20 in Table 5).
- SEQ ID NO: 131 The amino acid sequence of the synthetic peptide produced and used in Example 8 (peptide 21 in Table 5) is shown.
- SEQ ID NO: 132 The amino acid sequence of the synthetic peptide (peptide 22 in Table 5) prepared and used in Example 8 is shown.
- SEQ ID NO: 133 1 represents the amino acid sequence of the synthetic peptide produced and used in Example 8 (peptide 23 in Table 5).
- SEQ ID NO: 134 1 represents the amino acid sequence of the synthetic peptide prepared and used in Example 8 (peptide 24 in Table 5).
- SEQ ID NO: 135 1 represents the amino acid sequence of the synthetic peptide prepared and used in Example 8 (peptide 25 in Table 5).
- SEQ ID NO: 136 The amino acid sequence of the synthetic peptide produced and used in Example 8 (peptide 26 in Table 5) is shown.
- SEQ ID NO: 137 1 represents the amino acid sequence (Swiss-Prot: P06473) of the gB glycoprotein of human cytomegalovirus (HCMV).
- Table 1 shows the relationship between nucleotide or amino acid sequences appearing in Examples 1 to 6 of the present specification and SEQ ID NOs.
- Example 1 Isolation of fully human antibody-producing cell clones against HCMV A flowchart up to the isolation of antibody-producing cell clones is shown in FIG. B lymphocytes were isolated from human peripheral blood with high serum anti-HCMV antibodies and infected with EBV. Infected cells were seeded in a 96-well plate and cultured for about 3 weeks, and then the anti-HCMV antibody in the culture supernatant was screened (primary screening). Screening was performed using AD1 and AD2 (J. Virol., 65, 138-146 (1991), J. Gen. Virol., 73, 2375-2383 (1992), J. Virol. 66, 5290-5297 (1992), J.
- Example 2 Confirmation of antibody isotype and subclass Using the culture supernatant of the isolated antibody-producing cell clone, the isotype of the produced antibody was confirmed by ELISA (Reference: Curr Protoc Immunol. 2001 May; Chapter 2: Unit 2.2).
- the ELISA used was a 96-well plate coated with GST-fused HCMV-AD1 or AD2, and antibodies specific for each isotype and subclass were used as secondary antibodies.
- the isotype and subclass of the obtained anti-HCMV antibody are shown in Table 2.
- Example 3 Cloning of DNA encoding anti-HCMV antibody From total-RNA of antibody-producing cells, reverse transcription was performed using Oligo-dT primer, and the antibody gene was amplified by PCR using the obtained cDNA as a template. Primers used for PCR were designed based on a database of cDNA encoding human IgG antibody H chain and L chain. In order to amplify full length H chain cDNA and L chain cDNA, the 5 ′ terminal primer has a translation initiation point and the 3 ′ terminal primer has a translation termination point.
- Example 4 Determination of antibody amino acid sequence based on nucleotide sequence
- the antibody H chain and L chain cDNAs amplified by the PCR method were inserted into a plasmid vector, and the respective nucleotide sequences were confirmed by an ABI sequencer. From the obtained base sequence, the signal sequence and the amino acid sequences of the antibody H chain and L chain were determined.
- Kabat's method was used for analysis of the complementarity determining region (CDR) of the antibody (www.bioinf.org.uk: Dr. Andrew CR Martin's Group, Antibodies: General Information).
- CDR sequences of the obtained anti-HCMV antibody (EV2038) are shown in SEQ ID NOs: 13-18.
- the amino acid sequences of EV2038 H chain CDR1, H chain CDR2, H chain CDR3, L chain CDR1, L chain CDR2, and L chain CDR3 are SEQ ID NOS: 13, 14, 15, 16, 17, and 18, respectively. Shown in By the way, in order to examine the similarity with the monoclonal antibody reported as an AD1 antibody so far, the antibody whose variable region amino acid sequence is published in GenBank et al. was compared with the CDR sequence of EV2038. Various CDR sequences of known human or mouse-derived AD1 antibodies were determined by the Kabat method, and compared with the CDR sequences of EV2038 similarly determined.
- the homology of individual CDRs is the homology obtained from the number of amino acid residues to be compared (denominator) and the number of amino acid residues (molecules) whose position and type matched EV2038 in the CRD part. (%).
- the total (%) is the sum of the number of amino acid residues serving as the denominator and the number of amino acid residues serving as the numerator obtained by comparison of the individual CDRs.
- the homology (%) is obtained from the radix.
- EV2038 did not show any homology with known AD1 antibodies, and it was revealed that CDR sequences differ greatly from those reported so far.
- Embodiment 5 Confirmation that the obtained antibody gene encodes an anti-HCMV antibody
- the obtained H-chain and L-chain cDNAs were each inserted into an expression vector and simultaneously introduced into 293T cells. Gene transfer was performed under the conditions recommended by the manufacturer using Lipofectamine (Invitrogen) and Plus reagent (Invitrogen) (Invitrogen catalog: Cat.No.18324-111, Cat.No.18324-012, or Cat.No.18324-020). ).
- the culture supernatant was recovered, and the antibody in the culture supernatant was a human IgG antibody by ELISA using a 96-well plate coated with anti-human IgG antibody and GST-fused HCMV-AD1, and HCMV- It was confirmed to bind to AD1.
- Example 6 Production of antibody protein
- the resulting anti-HCMV antibody expression plasmid was introduced into CHO cells.
- the same method as in the case of 293T cells described above was employed for gene transfer.
- a selection marker By culturing in the presence of a selection marker, a CHO cell clone that constantly produces antibodies was obtained.
- CHO cells stably producing the antibody were cultured in a serum-free medium, and the culture supernatant was collected. This culture supernatant was added to a Protein A column, and a purified antibody was obtained by affinity purification.
- the column used was a pre-packed column of HiTrap rProtein A FF (GE Healthcare), and the purification conditions were those recommended by the column manufacturer.
- the HCMV-AD1 or HCMV-AD2 binding property of the antibody was confirmed by ELISA. Further, the antibody H chain of about 50 kDa and the antibody L chain of about 25 kDa were confirmed by SDS-PAGE.
- Example 7 Preparation of variants and their binding activity
- the CDR-H3 region (amino acid numbers 117 to 132) was examined in particular.
- the number of the amino acid residue of CDR-H3 is represented by the rank from the N-terminus (methionine) of the heavy chain amino acid sequence including the signal sequence shown in SEQ ID NO: 2.
- amino acids constituting natural proteins can be grouped according to their side chain characteristics.
- amino acids having similar characteristics include aromatic amino acids (tyrosine, phenylalanine, tryptophan), basic Amino acids (lysine, arginine, histidine), acidic amino acids (aspartic acid, glutamic acid), neutral amino acids (serine, threonine, asparagine, glutamine), amino acids with hydrocarbon chains (alanine, valine, leucine, isoleucine, proline), and It can be classified into other groups (glycine, methionine, cysteine).
- “conservative amino acid substitution” refers to substitution between amino acids with similar characteristics, that is, amino acid substitution mainly within the same group. This substitution is believed to not significantly affect the properties of the original protein or not significantly change it.
- “non-conservative amino acid substitution” refers to substitution with an amino acid having a characteristic greatly different from that of the original amino acid.
- EV2038 CDR-H3 variant One of the 16 amino acids constituting EV2038 CDR-H3 was subjected to non-conservative amino acid substitution using a two-step PCR method to obtain a variant (V117K, T118W, R119V, D120I, L121E, E122L, W123T, I124D, P125R, G126F, D127I, Y128N, Y129N, M130Q, D131I, V132K).
- variants with conservative amino acid substitutions in this region (V117L, V117I, T118S, T118K, R119K, R119T, D120E, D120A, E122D, E122A, D127E, D127A, Y128F, Y128W, Y129F, Y130F, Y130F, Y130F, Y130F, D131E, D131A, V132Y, V132S) were found to retain the binding ability in AD1 as in the case of non-conservative amino acid substitution (FIG. 5).
- Table 4 shows a list of SEQ ID NOs of the amino acid sequences (including signal sequences) of the variant H chains prepared in this section.
- Example 8 FIG. Epitope mapping of anti-HCMV AD1 antibody
- deletion mutations were introduced into the expression vector in which AD1 of HCMV gB was cloned, and various parts of AD1 were A series of E. coli mutants expressing the deleted protein were generated. After culturing and inducing expression of these mutant Escherichia coli, standard Western blot analysis was performed using cell lysate as an antigen. As controls, two types of EV2038 and variants having different binding sites and having the ability to bind to AD1 were selected as representatives.
- One of the selected variants is the 124th isoleucine moiety (non-conservative amino acid) located at the top of the CDR-H3 loop structure (Shirai, H., et al., FEBS Letters, 1996; 399: p1-8). It is a conservative amino acid substitution I124V at one of the sites where AD1 binding activity was not observed by substitution. The other is a non-conservative amino acid substitution V132K of the 132rd valine located at the root of the loop structure of CDR-H3.
- EV2038, I124V, and V132K all bind to clone numbers # 0, # 12, # 13, # 14, # 15, and # 19, and EV2038 and its variants both have : SEQ ID NO: 23), and 596-640 (EDNEILLGNHRTEECQLPSLKIFIAGNSAEYEYVDYLFKRMIDLSS: SEQ ID NO: 24) was found to have an epitope (FIGS. 9 and 10).
- amino acid sequence of gB of HCMV AD169 strain used as an antigen was described with reference to the sequence of accession number P06473, numbered in order from the methionine of the start codon.
- EV2038 For EV2038, more detailed epitopes were determined on the peptide array. Twenty-six peptides were synthesized by shifting the 12-residue peptide by 4 residues in the range of amino acid residues 548 to 641 (Table 5). Each peptide was coupled to the surface of the derivatized cellulose membrane at the C-terminus, and was solid-phase synthesized as a 3.7 mm ⁇ 3.7 mm individual spot (SPOTs method, Sigma Genosys). Determination of the peptide to which EV2038 binds was performed by standard dot blot analysis. EV2038 binds to Peptide Nos. 3, 7, 8, 21, and 22 (FIG.
- the epitope is amino acid residues 549-560 (SCVTINQTSVKV: SEQ ID NO: 25), amino acid residues 569-576 (SPGRCYSR: SEQ ID NO: 26) ), Amino acid residues 625 to 632 (YEYVDYLF: SEQ ID NO: 27).
- ITC52 or the like recognizes a discontinuous epitope of amino acid residues 570 to 579 and amino acid residues 606 to 619 (WO93 / 21952 and J. Virol, 67; p703-710 ( 1993)), but two epitope sequence portions excluding at least amino acid residues 569 to 576 (SPGRCYSR: SEQ ID NO: 26) were not observed in previous reports of AD1 antibody, and EV2038 has been It was shown that the antibody recognizes a discontinuous sequence different from the reported AD1 antibody (FIG. 10).
- Example 9 Neutralization activity evaluation (1) Immunostaining method Neutralization activity was confirmed as an efficacy evaluation of the anti-HCMV antibody (EV2038). The neutralizing activity was evaluated based on the inhibition rate of antibodies against HCMV (AD169 strain) infection on human fetal lung-derived normal fibroblasts (MRC-5: RIKEN BRC No. RCB0211). The method was modeled after Abai et al. (Journal of Immunological Methods 322 2007 82-93). In summary: Complement (5%) was added to the virus solution and purified antibody for 1 hour, and then inoculated into MRC-5 cells (37 ° C., 1 hour).
- IE1 which is an early protein of HCMV was detected by immunofluorescence staining. Measurement of HCMV-infected cells was performed with image analysis software Image J (http://rsbweb.nih.gov/ij/).
- FIG. 11 shows the results of evaluating the neutralizing activity of anti-HCMV antibodies.
- a human monoclonal antibody hIgG
- a mouse monoclonal antibody clone name HCMV16, AbD
- gH glycoprotein H
- serotec 2470-5437
- the 50% inhibitory concentration (IC 50 ) of EV2038 was 0.58 ⁇ g / mL, and it was confirmed that it has effective neutralizing activity at a lower concentration than EV2001.
- the effective neutralizing activity cannot be confirmed with EV2001, whereas the IC 50 of EV2038 is 0.57 ⁇ g / mL, confirming that it has a neutralizing activity equivalent to that in the presence of complement. (Table 6).
- Plaque method for EV2038 which showed high neutralizing activity in the above evaluation, further infection prevention by plaque method (Masuho, Y. et al., J. Gen. Virol., 1987; 68: p1457-1461) Activity was evaluated.
- As the virus strain AD169, Towne, Davis, Merlin strain and HCMV clinical isolates T-137 and MDU-1 represented as HCMV laboratory strains were used. The method is summarized as follows. 50-100 PFU of virus solution and serially diluted purified antibody at a predetermined concentration were mixed, incubated at 37 ° C. for 1 hour, and then monolayered in a 48-well microplate (MRC-5) or retinal pigment epithelium Cells (ARPE-19) were inoculated.
- MRC-5 48-well microplate
- ARPE-19 retinal pigment epithelium Cells
- the negative control is a human monoclonal antibody (hIgG) having no specificity for HCMV
- the positive control is an anti-CMV high-titer immunoglobulin preparation CytoGam approved in the US for prevention of HCMV infection associated with kidney transplantation.
- CSL Behring CytoGam Cytomegalovirus immune globulin intravenous, Prescribing information. (Revised July 2008)). It has been reported that HCMV has different invasion mechanisms depending on the mode of infection to fibroblasts and the mode of infection to epithelial cells and endothelial cells (Sinzger, C. et al., Curr Top Microbiol Immunol., 2008; 325: p63-83).
- HCMV is inherently infectious in a wide range of tissues and cell types in the body (Sinzger, C. et al., Curr Top Microbiol Immunol., 2008; 325: p63-83).
- the anti-HCMV antibody of the present invention exhibits an IC 50 of 0.012-0.037 ⁇ g / mL in infection of fibroblasts of a laboratory strain.
- the IC 50 is 0.044 ⁇ g / mL
- the fibroblast type and the epithelial cell / endothelial cell type had the same excellent neutralizing activity.
- EV2038 is about 2000 times as active as AD169 strain compared to the commercially available anti-CMV high-titer immunoglobulin preparation CytoGam, and has a track record of clinical development. Was about 20 times more active than literature values (Masuho, Y. et al., J. Gen. Virol., 1987; 68: p1457-1461).
- Example 10 Evaluation of Neutralizing Activity of EV2038 Variant Antibody Two variants with different substitution sites were selected from EV2038 variants, and the neutralizing activity was confirmed. One is a substitution of the amino acid at the 124th isoleucine part (the upper part of the loop structure of CDR-H3) in which non-conservative amino acid substitution was not observed but AD1 binding activity was observed, and a conservative amino acid substitution at that site I124V was used. The other is the non-conservative amino acid substitution V132K at the 132nd position (the root portion of the CDR-H3 loop structure) in which AD1 binding activity equivalent to that of the original was observed even in the non-conservative amino acid substitution. The method follows that of Abai et al.
- HCMV infection inhibition rate of each antibody was determined as a percentage of the infection inhibition rate when the same concentration of hIgG was added.
- IC 50 50% inhibitory concentration
- I124V was 0.45 ⁇ g / mL
- V132K was 1.20 ⁇ g / mL, and almost the same activity as EV2038 was observed.
- Example 11 Evaluation of intercellular infection inhibitory activity Further, as one of the evaluations of the efficacy of EV2038, human fetal lung-derived normal fibroblasts (MRC-5) infected with HCMV were used to evaluate the intercellular infection inhibitory activity of EV2038. .
- the evaluation method was based on the method of Navarro et al. (Virology. 1993; 197: p143-158). Specifically, MRC-5 that had been infected with HCMV (AD169) for 24 hours was used, and the antibody was added in a 4-fold dilution series from 10 mg / mL (about 67 nM). The cells were fixed 6 days after infection, and IE1, which is an early-expressed protein, was detected by immunostaining.
- Navarro et al. reported an example of 100-75% inhibition at a concentration of 10 mg / mL with the most active antibodies (such as CH177-3 and CH244-4).
- EV2038 showed 100-75% inhibition of cell infection in the concentration range of 10 to 0.63 ⁇ g / mL, and 75-50% even at 0.16 ⁇ g / mL (1.07 nM). Inhibition of intercellular infection was observed.
- the anti-HCMV antibody or antigen-binding fragment thereof according to the present invention can be used in various diseases caused by HCMV, such as interstitial pneumonia, retinitis, gastroenteritis, encephalitis in immunocompromised patients. It is considered to bring about a new approach as a preventive or therapeutic drug for diseases such as these, liver function abnormalities caused by HCMV infection in newborns and infants, interstitial pneumonia, and mononucleosis.
- the anti-HCMV antibody of the present invention and a pharmaceutical composition containing the antibody are various diseases caused by HCMV, such as (a) AIDS, cancer, after organ transplantation, after bone marrow transplantation, after hemodialysis, etc. Diseases such as interstitial pneumonia, retinitis, gastroenteritis, encephalitis, etc.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- General Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
Abstract
Description
HCMVは、種特異性が強く、ヒト以外の動物には感染しないが、ヒトには広く感染し、ヒトの体内においては広汎な組織に親和性がある。
しかも一度感染すると宿主の免疫が確立した後も排除されることなく終生保持されることとなる。
しかしながら、エイズ、癌、臓器移植後、骨髄移植後、血液透析後などの免疫不全状態においては、この潜伏感染していたHCMVの再活性化が起こり、間質性肺炎、網膜炎、胃腸炎、脳炎などの、場合によっては死に至る重篤なHCMV感染症を引き起こすことがある(非特許文献3、および4)。
又、胎児期に妊婦がHCMVの初感染を受け、妊婦から胎児へ胎盤を経由してHCMV感染が波及すると、先天性CMV感染症(congenital cytomegalovirus disease:巨細胞封入体症または先天性巨細胞封入体症(cytomegalic inclusion disease)とも呼ばれている。)を発症し、流産、死産、生後間もない死亡を引き起こす。または、死亡しない場合も低出生体重、肝脾腫、黄疸、血小板減少性紫斑病、小頭症、精神発育障害、知能発達遅延、脈絡網膜炎や聴覚障害などを引き起こすことがある。更に、新生児や乳児期においても、母親からのHCMV抗体の移行が不十分であった場合、産道、母乳、尿、または唾液などを介したHCMV感染により、肝機能異常、間質性肺炎、単核症などを発症する場合もある(非特許文献3,4,および5)。
ガンシクロビルは細胞内で活性型のガンシクロビル-三リン酸になり、DNAポリメラーゼの基質であるデオキシグアノシン-三リン酸(dGTP)と競合的に拮抗することにより、DNAポリメラーゼを阻害することでウイルスDNAの合成を妨害する抗ウイルス薬で、主にエイズなど免疫不全状態におけるサイトメガロウイルス網膜炎の治療や、CD4リンパ球数100/mm3以下の進行したHIV感染症におけるサイトメガロウイルス網膜炎の発症抑制に使用されており、医薬品としての認可も受けている。
しかしながら、ガンシクロビル等の抗ウイルス剤には造血障害など種々の副作用があることが報告されており、その使用態様は上記の如く、極限られたものとなる。
又、動物実験では催奇形性、変異原性、癌原性が報告されており、妊娠中は使用することができない。
その他、先天性HCMV感染症の重症例にガンシクロビルを使用することで、神経学的後遺症発現の減少や難聴の進行改善等の効果があるとされているが(非特許文献10)、やはりガンシクロビルの副作用である骨髄抑制、催奇形性、癌原性の問題については十分かつ慎重な検討が必要となる。
バルガンシクロビルは、ガンシクルビルのL-バリンエステルであり、経口投与されたのち腸管および肝臓のエステラーゼによりガンシクロビルに変換される。従って、作用機作および副作用はガンシクロビルと同じであり、骨髄抑制、催奇形性、癌原性の問題があり、日本では主にエイズなど免疫不全状態におけるサイトメガロウイルス網膜炎の治療薬としての承認が得られている。
一方、ホスカルネットは、ピロリン酸の類似物質でDNAポリメラーゼのピロリン酸結合部位に直接作用してDNAポリメラーゼを阻害することにより、HCMVの増殖を抑制する。ガンシクロビル耐性のHCMVに対しても有効である。主たる副作用としては、嘔気、貧血、血清クレアチニン上昇、嘔吐、低マグネシウム血症、低カリウム血症、知覚異常などがあり、特にショック、腎障害が高頻度で出現するので慎重な投薬が必要である。日本ではエイズ患者でHCMV網膜炎と確定診断された患者または臨床的にHCMV網膜炎が強く疑われる患者においてのみ使用が許可されており、感染予防の目的では使用しないこととされている(非特許文献8)。
一方、HCMVのワクチン開発に関しても鋭意行われているにもかかわらず、いまだ臨床使用に耐えられるものが得られていないのが現状である。
更にまた、近年はヒト由来の抗CMV高力価ガンマグロブリン製剤が開発され、米国においては、腎移植に伴うHCMV感染症の発症予防の適応で承認されている。しかしながら、抗CMV高力価ガンマグロブリン製剤はヒト由来の血液製剤であるため、さまざまな問題も抱えている。例えば、ヒト由来ガンマグロブリンの混合物であるがために、ロット間の活性のばらつきが大きいこと、かつ活性が低いこと、および供給量に限界があること、さらには未知の病原性ウイルスや病原体の混入などのリスクが常に付きまとっている等である。
そこで、HCMVに結合し、その感染性を中和すること(その生物学的活性を喪失させること)のできるモノクローナル抗体(以下「抗HCMV抗体」と称す場合がある)は、HCMVによる様々な病態の予防乃至治療薬として期待されることから、例えば、免疫不全状態の患者において、HCMVが原因となって引き起こされる様々な疾病に対する予防乃至治療戦略上、有用である。
即ち、HCMVの活性を喪失させて疾病の発症を予防、若しくは症状を緩和するのに、HCMVに対して強い親和性と高い中和能をもち、且つアレルギー反応を示さないヒト由来の抗HCMV抗体を、所謂「抗体医薬」として投与するのが特に有効であると考えられた。
その為、異物認識応答を起こさないヒトのモノクローナル抗体であって、HCMVに対する親和性、特異性および中和能に優れ、予防乃至治療薬としてもその活用を期待することのできる抗HCMV抗体、ならびにその抗原結合性断片の開発が強く望まれていた。
更には、昨今、HCMVの生体内での増殖を抑えるためには、中和活性のみならず、細胞間感染の阻止の重要性が指摘されており、(非特許文献12および13)、細胞間感染阻害活性を合わせ持つ抗HCMV抗体が切望されていた。
[2]ヒトサイトメガロウイルス(HCMV)gB糖タンパク質のAD1領域に特異的に結合し、その生物活性を中和し得るモノクローナル抗体であって、
(i)重鎖の可変領域が、
(a)配列番号13のアミノ酸配列、および配列番号13のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される重鎖CDR1のアミノ酸配列、
(b) 配列番号14のアミノ酸配列、および配列番号14のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される重鎖CDR2のアミノ酸配列、および、
(c)配列番号15のアミノ酸配列、配列番号15のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、および配列番号22で示されるアミノ酸配列からなる群から選択される重鎖CDR3のアミノ酸配列、ならびに
(ii)軽鎖の可変領域が、
(a)配列番号16のアミノ酸配列、および配列番号16のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される軽鎖CDR1のアミノ酸配列、
(b) 配列番号17のアミノ酸配列、および配列番号17のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される軽鎖CDR2のアミノ酸配列、および、
(c)配列番号18のアミノ酸配列、および配列番号18のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される軽鎖CDR3のアミノ酸配列、
を含有する抗体もしくはその抗原結合性断片。
[3]上記[2]に記載の抗体もしくはその抗原結合性断片であって、HCMV-gB糖タンパク質の549~580位の連続するアミノ酸残基からなるアミノ酸配列(配列番号23)および596~640位の連続するアミノ酸残基からなるアミノ酸配列(配列番号24)の領域に存在する2以上の不連続配列から成るエピトープに特異的に結合する、抗体もしくはその抗原結合性断片。
[4]上記[2]に記載の抗体もしくはその抗原結合性断片であって、HCMV-gB糖タンパク質のAD1領域にある配列番号25のアミノ酸配列、配列番号26のアミノ酸配列、および配列番号27のアミノ酸配列から成る不連続配列をエピトープとして認識する、抗体もしくはその抗原結合性断片。
[5]上記[3]または[4]に記載の抗体もしくはその抗原結合性断片であって、
(i)
(a)配列番号13のアミノ酸配列を含む重鎖CDR1のアミノ酸配列、
(b)配列番号14のアミノ酸配列を含む重鎖CDR2のアミノ酸配列、および、
(c)配列番号22のアミノ酸配列からなる群から選択される重鎖CDR3のアミノ酸配列、ならびに
(ii)
(a)配列番号16のアミノ酸配列を含む軽鎖CDR1のアミノ酸配列、
(b)配列番号17のアミノ酸配列を含む軽鎖CDR2のアミノ酸配列、および、
(c)配列番号18のアミノ酸配列を含む軽鎖CDR3のアミノ酸配列、
を含有する抗体もしくはその抗原結合性断片。
[6]上記[5]に記載の抗体もしくはその抗原結合性断片であって、
(i)
(a)配列番号13のアミノ酸配列を含む重鎖CDR1のアミノ酸配列、
(b)配列番号14のアミノ酸配列を含む重鎖CDR2のアミノ酸配列、および、
(c)配列番号15のアミノ酸配列を含む重鎖CDR3のアミノ酸配列、ならびに
(ii)
(a)配列番号16のアミノ酸配列を含む軽鎖CDR1のアミノ酸配列、
(b)配列番号17のアミノ酸配列を含む軽鎖CDR2のアミノ酸配列、および、
(c)配列番号18のアミノ酸配列を含む軽鎖CDR3のアミノ酸配列、
を含有する、抗体もしくはその抗原結合性断片。
[7]上記[2]に記載の抗体もしくはその抗原結合性断片であって、
(a) 配列番号10のアミノ酸配列、配列番号10のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、もしくはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、または配列番号10のアミノ酸配列と95%以上の同一性を有するアミノ酸配列からなる重鎖可変領域(HCVR)、ならびに
(b) 配列番号12のアミノ酸配列、配列番号12のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、もしくはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、または配列番号12のアミノ酸配列と95%以上の同一性を有するアミノ酸配列からなる軽鎖可変領域(LCVR)を含有する、抗体もしくはその抗原結合性断片。
[8]上記[7]に記載の抗体もしくはその抗原結合性断片であって、
(a)配列番号10のアミノ酸配列を含む重鎖可変領域(HCVR)、および
(b) 配列番号12のアミノ酸配列を含む軽鎖可変領域(LCVR)を含有する、抗体もしくはその抗原結合性断片。
[9]上記[2]に記載の抗体もしくはその抗原結合性断片であって、
(a) 配列番号2もしくは6のアミノ酸配列、配列番号2もしくは6のアミノ酸配列において、1~数個のアミノ酸残基の欠失、置換、挿入、付加、もしくはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、または配列番号2もしくは6のアミノ酸配列と95%以上の同一性を有するアミノ酸配列で示される重鎖(H鎖)、ならびに
(b) 配列番号4もしくは8のアミノ酸配列、配列番号4もしくは8のアミノ酸配列において、1~数個のアミノ酸残基の欠失、置換、挿入、付加、もしくはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、または配列番号4もしくは8のアミノ酸配列と95%以上の同一性を有するアミノ酸配列で示される軽鎖(L鎖)を含有する、抗体もしくはその抗原結合性断片;
[10]上記[9]に記載の抗体もしくはその抗原結合性断片であって、
(a)配列番号2または6のアミノ酸配列を含む重鎖(H鎖)、および
(b)配列番号4または8のアミノ酸配列を含む軽鎖(L鎖)を含有する、抗体もしくはその抗原結合性断片。
[11]上記抗体がヒトモノクローナル抗体である、上記[1]~[10]のいずれかに記載の抗体またはその抗原結合性断片。
[12]上記抗体のクラス(サブクラス)がIgG1(λ)である、上記[1]~[11]のいずれかに記載の抗体またはその抗原結合性断片。
[13]HCMVの実験室株(AD169)に対するヒト繊維芽細胞下での50%プラーク形成阻止濃度が0.05μg/mL(約0.3nM)以下である上記[1]~[12]のいずれかに記載の抗体またはその抗原結合性断片。
[14]ヒト繊維芽細胞(MRC-5)にあらかじめHCMVの実験室株(AD169)を感染させた系で、0.2μg/mL(約1.3nM)以下で50%以上の細胞間感染阻止能を有する上記[1]~[13]のいずれかに記載の抗体またはその抗原結合性断片。
[15]上記[1]~[14]のいずれかに記載の抗体またはその抗原結合性断片および薬学的に許容可能な担体を含む、ヒトサイトメガロウイルス(HCMV)が関与する疾患を予防または治療するための医薬組成物。
[16]HCMVが関与する疾患が、(a)免疫不全状態におけるHCMVの再活性化による間質性肺炎、網膜炎、胃腸炎、もしくは脳炎、(b)妊婦から胎児へHCMV感染が波及することによる先天性CMV感染症、(c)上記先天性CMV感染症により引き起こされる流産、死産、生後間もない死亡、(d)上記先天性CMV感染症により死亡しない場合における低出生体重、肝脾腫、黄疸、血小板減少性紫斑病、小頭症、精神発育障害、知能発達遅延、脈絡網膜炎、もしくは聴覚障害、または(e)新生児もしくは乳児期におけるHCMV感染により発症する肝機能異常、間質性肺炎、もしくは単核症である、上記[15]に記載の医薬組成物。
[17]HCMVgB糖タンパク質のAD1領域に特異的に結合し、その生物活性を中和し得る抗HCMVモノクローナル抗体またはその抗原結合性断片をコードする核酸であって、配列番号2、4、6、8、10、12、13~18、および22からなる群から選択されるアミノ酸配列をコードする核酸、および該核酸と高ストリンジェントな条件下でハイブリダイズする核酸から選択される単離された核酸。
[18]上記[17]に記載の核酸を組込んだベクター。
[19]上記[18]に記載のベクターが導入された宿主細胞。
[20]上記[19]に記載の宿主細胞を培養する工程を含む、上記[1]~[14]のいずれかに記載の抗体または抗原結合性断片の作製方法。
(2)HCMVの感染に必須のgB糖タンパク質の中でも、AD1領域はgBの機能や立体構造の形成に必須の部分であり(Qadri,I. et al., Assembly of conformational-dependent neutralizing domains on glycoprotein B of human cytomegalovirus. J.Gen.Virol,1992; 73; p2913-2921;およびBritt, W.J. et al., Antigenic domain is required for oligomerization of human cytomegalovirus glycoprotein B. J.Virol.,2005; 79: p4066-4079)、かつ臨床分離のウイルス株でも変異の少ない部分として知られており、AD1に対する抗体は幅広いスペクトルを有する可能性がある。
(3)AD2領域の抗体に比べ、gB上の長い領域に及ぶ不連続エピトープを認識するAD1抗体は特異性が高く、他の生体分子との交差反応により予期せぬ副作用を生ずる可能性は低いと考えられる。
本願発明の一実施形態によれば、ヒトサイトメガロウイルス(HCMV)のgB糖タンパク質に特異的に結合し、その生物活性を中和し得る抗体またはその抗原結合性断片が提供される。より具体的な実施形態では、HCMVのgB糖タンパク質のAD1領域に存在する不連続エピトープに特異的に結合し、該タンパク質の生物活性を中和し得る抗体またはその抗原結合性断片が提供される。
「ヒトサイトメガロウイルス(HCMV)のgB糖タンパク質のAD1領域」または「HCMV gB糖タンパク質AD1領域」とは、HCMV gB糖タンパク質のアミノ酸配列中の552-635位の連続するアミノ酸残基からなる領域のことをいう(Wagnerら, Journal of Virology, Vol. 66, No. 9, Sept. 1992, p.5290-5297)。
本明細書中、「エピトープ」とは、当該分野で通常使用される意味で使用され、抗体が結合する相手としての、抗原分子の小さな部分構造を意味する(岩波 生物学事典 第4版(1996年第1刷発行))。
(a)配列番号2または6のアミノ酸配列を含む重鎖(H鎖)、および
(b)配列番号4または8のアミノ酸配列を含む軽鎖(L鎖)を含有し、この抗体または抗原結合性断片は、ヒトサイトメガロウイルスのgB糖タンパク質に特異的に結合し、その生物活性を中和し得る。
(a)配列番号10のアミノ酸配列を含む重鎖可変領域(HCVR)、および
(b) 配列番号12のアミノ酸配列を含む軽鎖可変領域(LCVR)を含有し、ヒトサイトメガロウイルスのgB糖タンパク質に特異的に結合し、その生物活性を中和し得る。
(i)重鎖の可変領域のCDR(Complementarity Determining Region)1、CDR2、およびCDR3のアミノ酸配列が、それぞれ、
(a)配列番号13のアミノ酸配列、
(b) 配列番号14のアミノ酸配列、および、
(c)配列番号15のアミノ酸配列、
を含有し、
(ii)軽鎖の可変領域のCDR1、CDR2、およびCDR3のアミノ酸配列が、それぞれ、
(a)配列番号16のアミノ酸配列、
(b) 配列番号17のアミノ酸配列、および、
(c)配列番号18のアミノ酸配列、
を含有し、ヒトサイトメガロウイルスのgB糖タンパク質に特異的に結合し、その生物活性を中和し得る。
(a)配列番号2もしくは6のアミノ酸配列において、1~数個のアミノ酸残基の欠失、置換、挿入、付加、もしくはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、または配列番号2もしくは6のアミノ酸配列と95%以上の同一性を有するアミノ酸配列で示される重鎖(H鎖)、ならびに
(b)配列番号4もしくは8のアミノ酸配列において、1~数個のアミノ酸残基の欠失、置換、挿入、付加、もしくはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、または配列番号4もしくは8のアミノ酸配列と95%以上の同一性を有するアミノ酸配列で示される軽鎖(L鎖)を含有する。
(a)配列番号10のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、もしくはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、または配列番号10のアミノ酸配列と95%以上の同一性を有するアミノ酸配列からなる重鎖可変領域(HCVR)、ならびに
(b)配列番号12のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、もしくはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、または配列番号12のアミノ酸配列と95%以上の同一性を有するアミノ酸配列からなる軽鎖可変領域(LCVR)を含有する。
(i)
(a)配列番号13のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される重鎖CDR1、
(b)配列番号14のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される重鎖CDR2、および
(c)配列番号15のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、および配列番号22で示されるアミノ酸配列からなる群から選択される重鎖CDR3、ならびに
(ii)
(a)配列番号16のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される軽鎖CDR1、
(b)配列番号17のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される軽鎖CDR2、および
(c)配列番号18のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される軽鎖CDR3を含有する。
「HCMVの生物活性を中和し得る抗体」とは、HCMVもしくはHCMV感染細胞に結合することによってHCMVの生物活性を阻害する抗体を指すものとする。
「HCMVの生物活性」としては、代表的には、以下(a)~(e)に例示する疾患を引き起こすHCMVの活性が含まれるが、これらに限定されず、活性化されたHCMVの活動が原因で引き起こされる種々の疾患を誘発するHCMVの活性が含まれる:
(a)エイズ、癌、臓器移植後、骨髄移植後、血液透析後などの免疫不全状態におけるHCMVの再活性化による間質性肺炎、網膜炎、胃腸炎、脳炎などの様々な病気;
(b)妊婦から胎児へHCMV感染が波及することによる先天性CMV感染症;
(c)前記先天性CMV感染症により引き起こされる流産、死産、生後間もない死亡;
(d)前記先天性CMV感染症により死亡しない場合における低出生体重、肝脾腫、黄疸、血小板減少性紫斑病、小頭症、精神発育障害、知能発達遅延、脈絡網膜炎や聴覚障害;
(e)新生児や乳児期におけるHCMV感染により発症する肝機能異常、間質性肺炎、単核症等(非特許文献3、4、および5)。
そのために、もとの抗体のものと同様な結合特性を有するインタクト組換え抗体を作り直す際に、特定の抗体の配列全体を得る必要はない。その抗体の重鎖および軽鎖の可変部領域配列若しくはCDR部分の配列があれば、この目的にとって充分な場合もある。
CDR以外のアミノ酸配列は特に限定されず、CDR以外のアミノ酸配列が他の抗体、特に、他種の抗体由来である、いわゆるCDR移植抗体も本発明の抗体に包含される。この内、CDR以外のアミノ酸配列もヒト由来である抗体が好ましいが、必要に応じてフレームワーク領域(FR)に1ないし数個(具体的な数は上記と同様)のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異があってもよい。これら抗体の作製方法は公知の方法を用いることができる(Riechmann L, et al., Reshaping human antibodies for therapy. Nature, 332:323-327, 1988)。本発明においては、勿論、完全ヒト抗体が好ましい。
ところで、自然界のタンパク質を構成しているアミノ酸は、それらの側鎖の特性によって群分け可能であり、例えば、同様な特性を有するアミノ酸群としては、芳香族アミノ酸(チロシン、フェニルアラニン、トリプトファン)、塩基性アミノ酸(リジン、アルギニン、ヒスチジン)、酸性アミノ酸(アスパラギン酸、グルタミン酸)、中性アミノ酸(セリン、トレオニン、アスパラギン、グルタミン)、炭化水素鎖を有するアミノ酸(アラニン、バリン、ロイシン、イソロイシン、プロリン)、およびその他(グリシン、メチオニン、システイン)の群などに分類できる。
非天然型のアミノ酸も含めた相互に置換可能なアミノ酸残基の例としては、下記の様な群わけもあり、同一群に含まれるアミノ酸残基は相互に置換可能である。A群:ロイシン、イソロイシン、ノルロイシン、バリン、ノルバリン、アラニン、2-アミノブタン酸、メチオニン、o-メチルセリン、t-ブチルグリシン、t-ブチルアラニン、シクロヘキシルアラニン; B群:アスパラギン酸、グルタミン酸、イソアスパラギン酸、イソグルタミン酸、2-アミノアジピン酸、2-アミノスベリン酸; C群:アスパラギン、グルタミン; D群:リジン、アルギニン、オルニチン、2,4-ジアミノブタン酸、2,3-ジアミノプロピオン酸; E群:プロリン、3-ヒドロキシプロリン、4-ヒドロキシプロリン; F群:セリン、スレオニン、ホモセリン; G群:フェニルアラニン、チロシン、トリプトファン。
本発明において、さらに好ましい抗体は、(a)配列番号6のアミノ酸配列;配列番号6のアミノ酸配列において、1~数個(具体的な数は上記と同様)のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列;または配列番号6のアミノ酸配列と95%以上(具体的な%は上記と同様)の同一性を有するアミノ酸配列で示される重鎖(H鎖)、および(b)配列番号8のアミノ酸配列;配列番号8のアミノ酸配列において、1~数個(具体的な数は上記と同様)のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列;または配列番号8のアミノ酸配列と95%以上(具体的な%は上記と同様)の同一性を有するアミノ酸配列で示される軽鎖(L鎖)を含有する。
ここで「特異的に結合する」とは、所定の抗原を認識してそれに結合すること言う。
典型的には、本発明の抗体のHCMV(特に、ヒトHCMV)との解離定数(Kd値)は、好ましくは1×10-7M以下、より好ましくは1×10-8M以下、さらに好ましくは1×10-9M以下であり、最も好ましくは1×10-10M以下である。抗体とHCMVとの解離定数を測定するには、公知の方法を用いることができる。例えば、チップ上に固定化した抗HCMV抗体を用いてBIACORET100(登録商標)のような蛋白質相互作用解析装置により測定することができる。
本発明に係る抗HCMV抗体またはその抗原結合性断片は、好ましくは、AD169株に対する中和活性として、1μg/mL(約7nM)以下、より好ましくは、0.1μg/mL(約0.7nM)以下で、さらにより好ましくは0.05μg/mL(約0.3nM)以下で、最も好ましくは約0.03μg/mL(約0.2nM)以下で約50%のプラーク形成阻止能を有する。
また、細胞間感染阻止能としては、あらかじめHCMVに感染した細胞を一定時間培養後、その細胞培養系に種々の濃度の抗HCMV抗体を添加することにより、細胞間感染の阻害効果を評価することが出来る。
本発明に係る抗HCMV抗体またはその抗原結合性断片は、好ましくは、終濃度2μg/mL(約13nM)以下、より好ましくは、0.5μg/mL(約3nM)以下で、さらにより好ましくは0.2μg/mL(約0.13nM)以下で50%以上の細胞間感染阻止能を有する。
例えば、重鎖および軽鎖のシグナル配列はタンパク質成熟の過程で切断され、最終的な抗体の特性には寄与しないが、欠けている配列を追加するためには、クローン化されたcDNA配列を、ライゲーションまたはPCR増幅法により、合成オリゴヌクレオチドに組み合わせることができる。
代替的には、可変領域全体を一組の短い、重複のあるオリゴヌクレオチドとして合成し、PCR増幅法で組み合わせて、完全に人工的な可変領域クローンを作製することもできる。
本願発明の別の実施形態によれば、HCMVに特異的に結合し、その生物活性を中和し得る抗HCMVモノクローナル抗体またはその抗原結合性断片をコードする核酸であって、配列番号2、4、6、8、10、12、13~18および22からなる群から選択されるアミノ酸配列をコードする核酸、および該核酸と高ストリンジェントな条件下でハイブリダイズする核酸から選択される単離された核酸が提供される。
好ましくは、上記核酸はDNAまたはRNAであり、より好ましくはDNAである。
HCMVに結合し、その生物活性を中和し得る抗HCMVモノクローナル抗体またはその抗原結合性断片をコードする核酸であって、2、4、6、8、10、12、13~18および22からなる群から選択されるアミノ酸配列をコードする核酸と高い同一性を有する単離された核酸も本願発明に含まれる。ここで、「高い同一性を有する」とは、高ストリンジェントな条件下で所定の核酸配列に対してハイブリダイズすることができる程度の配列同一性を意味し、例えば、60%、70%、80%、90%、または95%、またはそれを超える同一性を有することを意味する。
「高ストリンジェントな条件」は、例えば、5×SSC、5×デンハルト溶液、0.5%SDS、50%ホルムアミド、50℃の条件である(例えば、J.SambrookらのMolecular Cloning, A Laboratory Manual 2nd ed.,Cold Spring Harbor Laboratory Press(1989), 特に11.45節"Conditions for Hybridization of Oligonucleotide Probes"参照)。これらの条件において、温度を上げるほど高い同一性を有するポリヌクレオチド(例えば、DNA)が効率的に得られることが期待できる。ただし、ハイブリダイゼーションのストリンジェンシーに影響する要素としては温度、プローブ濃度、プローブの長さ、イオン強度、時間、塩濃度など複数の要素が考えられ、当業者であればこれら要素を適宜選択することで同様のストリンジェンシーを実現することが可能である。
塩基配列の同一性は、上述した同一性検索アルゴリズムなどを利用して決定することが出来る(Proc. Natl. Acad.Sci. USA 872264-2268, 1990; Proc Natl Acad Sci USA 90: 5873, 1993)。
なお、本発明で好ましい核酸は、配列番号10および12のアミノ酸配列を共にコードするDNA、さらに好ましくは、配列番号6および8のアミノ酸配列を共にコードするDNAである。さらにより好ましい核酸は、配列番号2および4のアミノ酸配列を共にコードするDNAである。
もっとさらにより好ましい核酸は、配列番号5および7の核酸を共に含む核酸であり、さらにより好ましい核酸は、配列番号1ならびに3の核酸の両方を含む核酸である。
本発明は、上記核酸を組込んだベクターおよびそのベクターが導入された宿主細胞、これらを用いる抗体の作製方法にも関する。
本発明の抗体は、公知の方法を用いた組換えヒト抗体としても作製できる(Nature,312:643,1984 、Nature,321:522,1986など参照)。例えば、本発明の抗体は、本発明に係るベクターを導入した宿主細胞を培養し、培養上清などから、産生された抗体を精製することによって作製することができる。より具体的には、VHおよびVLをコードするcDNAを同一細胞または別のヒト細胞より作製したヒト抗体CHおよび/またはヒト抗体CLをコードする遺伝子を含有する動物細胞用発現ベクターにそれぞれ挿入してヒト抗体発現ベクターを構築し、動物細胞へ導入し発現させることにより製造することができる。
発現ベクターを導入する宿主細胞としては、必ずしも限定されないが、蛋白質遺伝子等の発現に汎用され、特に抗体遺伝子の発現に適合する細胞が好ましい。例えば、細菌(大腸菌等)、放線菌、酵母、昆虫細胞(SF9等)、哺乳類細胞(COS-1、CHO、ミエローマ細胞等)が挙げられる。
抗体の精製は、塩析法、ゲル濾過法、イオン交換クロマト法またはアフィニティークロマト法等の公知の精製手段を用いて行うことができる。
また更には、近年開発された抗体の糖鎖部分の修飾により抗体のADCC活性を大幅に改善するポテリジェント(Potellegent)技術を本願発明の抗体に応用して得られた抗体(Niwa R., et al, Clin.Cancer Res., 10,6248-6255(2004)参照)や、CDC活性を改善するコンプリジェント(Complegnent)技術を本願発明の抗体に応用して得られた抗体(Kanda S., et al, Glycobiology, 17, 104-118(2007)参照)も、本発明の技術範囲に属する。
本発明に係る抗HCMVモノクローナル抗体またはその抗原結合性断片は、健常人などの血液由来の抗体産生細胞から得ることができ、それは完全ヒト抗体である。この完全ヒト抗体は、抗体医薬として人体に投与したとしても、免疫原性を有さず、免疫反応は見られないものと考えられる。
なお、本願発明の抗HCMVモノクローナル抗体においては、従来の抗HCMVモノクローナル抗体よりさらに高い中和能を有するため、より少ない投与量で同程度の治療効果が期待できる。
健常人の血液からBリンパ球を分離し、該Bリンパ球の増殖を誘導する。増殖誘導の方法自体は公知であり、例えばガンの誘因因子となる「エプスタイン・バールウイルス(EBウイルス)」(Epstein-Barr virus)(以下、EBVと称す)を用いたトランスフォーム法(D.Kozborら)により、行うことができる。
即ち、上記Bリンパ球をEBVに感染させて増殖誘導し、増殖させた細胞を抗体産生細胞ライブラリとする。
増殖誘導させた細胞からモノクローナル抗体を回収する方法はモノクローナル抗体の作製 において常用されている周知の方法により行うことができる。
前記抗体産生細胞ライブラリの中からHCMVに結合する抗体を作り出すリンパ球クローンを選別、その培養上清から抗体を取り出す。即ち、前記抗体産生細胞ライブラリから限界希釈法によりHCMVに結合する抗体を産生する細胞集団(クローン)を選択する。
HCMVと結合するクローンの検出には、HCMV由来の抗原および標識マウス抗ヒトIgG抗体を用いたELISAを採用するのが好ましい。
選択された抗体陽性細胞集団を培養し、スクリーニングを繰り返すことによって、目的とする抗体のみを産生する細胞集団(クローン)を得ることができる
以上の抗体産生細胞クローンの分離までの工程を表すフローチャートを図1に示す。
抗HCMV抗体を精製するには、選抜された細胞を、ローラ瓶、2リットル入りスピナー・フラスコ、または他の培養系で増殖させることができる。
得られた培養上清を濾過し、濃縮してからプロテインAあるいはプロテインG-セファロース(GEヘルスケア社)などによるアフィニティ・クロマトグラフィにかけて当該タンパク質を精製することができる。緩衝液をPBSに交換し、OD280または好ましくはネフェロメータ分析により、濃度を判定できる。
アイソタイプはアイソタイプ抗原に特異的な方法で調べることができる。
又、抗体産生細胞クローン作製に関して、Bリンパ球に感染して増殖誘導させる活性があるEBウイルスを利用している点も特徴である。
EBウイルス法の利点は、ヒトの体内で作られるナチュラルな抗体を作製できる点および親和性の高い抗体が得られる点である。例えば、HCMVに対するヒト抗体は、マウスを人工的に免疫して作られた抗体より約10~100倍親和性が高いことが判明している。
EBウイルス感染で増殖したBリンパ球集団は抗体産生細胞のライブラリとなる。
このライブラリから特定の抗体産生細胞クローンを分離しヒト抗体を得ることができる。
次に、本発明は、上記抗体またはその抗原結合部分および薬学的に許容可能な担体を含む、ヒトサイトメガロウイルス(HCMV)が関与する疾患を予防または治療するための医薬組成物を提供する。
医薬品として許容される担体の例には、水、塩類溶液、リン酸緩衝化生理食塩水、デキ
ストロース、グリセロール、エタノールなどの1種または複数、ならびにこれらの組合せが含まれる。注射剤などとして使用される場合、pH調節剤や等張剤、例えば糖や、マンニトール、ソルビトールなどのポリアルコール、または塩化ナトリウムを組成物中に含むことが好ましい。医薬品として許容される担体には、さらに、湿潤剤や乳化剤、防腐剤、緩衝剤、安定化剤など、抗体または抗体部分の保存性または有効性を増大させる少量の補助物質を含めることができる。
配列番号1
シグナル配列を含む、HCMVのgB糖タンパク質のAD1領域に対する抗体(以下、「抗AD1抗体」)(EV2038)のH鎖をコードするヌクレオチド配列を表す。
配列番号2
シグナル配列を含む、抗AD1抗体(EV2038)のH鎖のアミノ酸配列を表す。
配列番号3
シグナル配列を含む、抗AD1抗体(EV2038)のL鎖をコードするヌクレオチド配列を表す。
配列番号4
シグナル配列を含む、抗AD1抗体(EV2038)のL鎖のアミノ酸配列を表す。
配列番号5
シグナル配列を含まない、抗AD1抗体(EV2038)のH鎖をコードするヌクレオチド配列を表す。
配列番号6
シグナル配列を含まない、抗AD1抗体(EV2038)のH鎖のアミノ酸配列を表す。
配列番号7
シグナル配列を含まない、抗AD1抗体(EV2038)のL鎖をコードするヌクレオチド配列を表す。
配列番号8
シグナル配列を含まない、抗AD1抗体(EV2038)のL鎖のアミノ酸配列を表す。
配列番号9
抗AD1抗体(EV2038)のH鎖可変領域をコードするヌクレオチド配列を表す。
配列番号10
抗AD1抗体(EV2038)のH鎖可変領域のアミノ酸配列を表す。
配列番号11
抗AD1抗体(EV2038)のL鎖可変領域をコードするヌクレオチド配列を表す。
配列番号12
抗AD1抗体(EV2038)のL鎖可変領域のアミノ酸配列を表す。
配列番号13
抗AD1抗体(EV2038)のH鎖CDR1のアミノ酸配列を表す。
配列番号14
抗AD1抗体(EV2038)のH鎖CDR2のアミノ酸配列を表す。
配列番号15
抗AD1抗体(EV2038)のH鎖CDR3のアミノ酸配列を表す。
配列番号16
抗AD1抗体(EV2038)のL鎖CDR1のアミノ酸配列を表す。
配列番号17
抗AD1抗体(EV2038)のL鎖CDR2のアミノ酸配列を表す。
配列番号18
抗AD1抗体(EV2038)のL鎖CDR3のアミノ酸配列を表す。
配列番号19
実施例でEV2038 CDR-H3バリアントを作製する際に使用した38 Hind-Sプライマーのヌクレオチド配列を表す。
配列番号20
実施例でEV2038のCDR-H3バリアントを作製する際に使用した38 Not-Aプライマーのヌクレオチド配列を表す。
配列番号21
実施例でEV2038のCDR-H3バリアントを作製する際に使用した塩基配列確認用プライマーのヌクレオチド配列を表す。
配列番号22
抗AD1抗体のCDR-H3のアミノ酸配列中のコンセンサスアミノ酸配列を表す。
配列番号23
実施例に示す欠失変異法によりエピトープが存在する領域として同定されたHCMV gB糖タンパク質AD1領域の549位~580位までのアミノ酸残基からなるアミノ酸配列を表す。
配列番号24
実施例に示す欠失変異法によりエピトープが存在する領域として同定されたHCMV gB糖タンパク質AD1領域の596位~640位までのアミノ酸残基からなるアミノ酸配列を表す。
配列番号25
実施例に示すペプチドアレイ法によりエピトープ領域として同定されたHCMV gB糖タンパク質AD1領域の549位~560位までのアミノ酸残基からなるアミノ酸配列を表す。
配列番号26
実施例に示すペプチドアレイ法によりエピトープ領域として同定されたHCMV gB糖タンパク質AD1領域の569位~576位までのアミノ酸残基からなるアミノ酸配列を表す。
配列番号27
実施例に示すペプチドアレイ法によりエピトープ領域として同定されたHCMV gB糖タンパク質AD1領域の625位~632位までのアミノ酸残基からなるアミノ酸配列を表す。
配列番号28
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の117位のバリン(V)をリジン(K)に置換した変異体のアミノ酸配列を表す。
配列番号29
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の118位のトレオニン(T)をトリプトファン(W)に置換した変異体のアミノ酸配列を表す。
配列番号30
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の119位のアルギニン(R)をバリン(V)に置換した変異体のアミノ酸配列を表す。
配列番号31
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の120位のアスパラギン酸(D)をイソロイシン(I)に置換した変異体のアミノ酸配列を表す。
配列番号32
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の121位のロイシン(L)をグルタミン酸(E)に置換した変異体のアミノ酸配列を表す。
配列番号33
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の122位のグルタミン酸(E)をロイシン(L)に置換した変異体のアミノ酸配列を表す。
配列番号34
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の123位のトリプトファン(W)をトレオニン(T)に置換した変異体のアミノ酸配列を表す。
配列番号35
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の124位のイソロイシン(I)をアスパラギン酸(D)に置換した変異体のアミノ酸配列を表す。
配列番号36
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をアルギニン(R)に置換した変異体のアミノ酸配列を表す。
配列番号37
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の126位のグリシン(G)をフェニルアラニン(F)に置換した変異体のアミノ酸配列を表す。
配列番号38
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の127位のアスパラギン酸(D)をイソロイシン(I)に置換した変異体のアミノ酸配列を表す。
配列番号39
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の128位のチロシン(Y)をアスパラギン(N)に置換した変異体のアミノ酸配列を表す。
配列番号40
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の129位のチロシン(Y)をアスパラギン(N)に置換した変異体のアミノ酸配列を表す。
配列番号41
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の130位のメチオニン(M)をグルタミン(Q)に置換した変異体のアミノ酸配列を表す。
配列番号42
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の131位のアスパラギン酸(D)をイソロイシン(I)に置換した変異体のアミノ酸配列を表す。
配列番号43
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の132位のバリン(V)をリジン(K)に置換した変異体のアミノ酸配列を表す。
配列番号44
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の121位のロイシン(L)をイソロイシン(I)に置換した変異体のアミノ酸配列を表す。
配列番号45
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の121位のロイシン(L)をバリン(V)に置換した変異体のアミノ酸配列を表す。
配列番号46
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の121位のロイシン(L)をアラニン(A)に置換した変異体のアミノ酸配列を表す。
配列番号47
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の121位のロイシン(L)をフェニルアラニン(F)に置換した変異体のアミノ酸配列を表す。
配列番号48
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の121位のロイシン(L)をプロリン(P)に置換した変異体のアミノ酸配列を表す。
配列番号49
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の123位のトリプトファン(W)をチロシン(Y)に置換した変異体のアミノ酸配列を表す。
配列番号50
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の123位のトリプトファン(W)をフェニルアラニン(F)に置換した変異体のアミノ酸配列を表す。
配列番号51
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の123位のトリプトファン(W)をプロリン(P)に置換した変異体のアミノ酸配列を表す。
配列番号52
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の123位のトリプトファン(W)をロイシン(L)に置換した変異体のアミノ酸配列を表す。
配列番号53
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の123位のトリプトファン(W)をイソロイシン(I)に置換した変異体のアミノ酸配列を表す。
配列番号54
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の124位のイソロイシン(I)をロイシン(L)に置換した変異体のアミノ酸配列を表す。
配列番号55
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の124位のイソロイシン(I)をメチオニン(M)に置換した変異体のアミノ酸配列を表す。
配列番号56
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の124位のイソロイシン(I)をプロリン(P)に置換した変異体のアミノ酸配列を表す。
配列番号57
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の124位のイソロイシン(I)をバリン(V)に置換した変異体のアミノ酸配列を表す。
配列番号58
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の124位のイソロイシン(I)をアラニン(A)に置換した変異体のアミノ酸配列を表す。
配列番号59
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の126位のグリシン(G)をプロリン(P)に置換した変異体のアミノ酸配列を表す。
配列番号60
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の126位のグリシン(G)をアラニン(A)に置換した変異体のアミノ酸配列を表す。
配列番号61
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の126位のグリシン(G)をセリン(S)に置換した変異体のアミノ酸配列を表す。
配列番号62
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の126位のグリシン(G)をアスパラギン(N)に置換した変異体のアミノ酸配列を表す。
配列番号63
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の126位のグリシン(G)をトレオニン(T)に置換した変異体のアミノ酸配列を表す。
配列番号64
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をグリシン(G)に置換した変異体のアミノ酸配列を表す。
配列番号65
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をイソロイシン(I)に置換した変異体のアミノ酸配列を表す。
配列番号66
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をアラニン(A)に置換した変異体のアミノ酸配列を表す。
配列番号67
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をロイシン(L)に置換した変異体のアミノ酸配列を表す。
配列番号68
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をバリン(V)に置換した変異体のアミノ酸配列を表す。
配列番号69
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をセリン(S)に置換した変異体のアミノ酸配列を表す。
配列番号70
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をトレオニン(T)に置換した変異体のアミノ酸配列を表す。
配列番号71
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をアスパラギン(N)に置換した変異体のアミノ酸配列を表す。
配列番号72
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をグルタミン(Q)に置換した変異体のアミノ酸配列を表す。
配列番号73
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をアスパラギン酸(D)に置換した変異体のアミノ酸配列を表す。
配列番号74
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をグルタミン酸(E)に置換した変異体のアミノ酸配列を表す。
配列番号75
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をリジン(K)に置換した変異体のアミノ酸配列を表す。
配列番号76
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をヒスチジン(H)に置換した変異体のアミノ酸配列を表す。
配列番号77
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をシステイン(C)に置換した変異体のアミノ酸配列を表す。
配列番号78
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をメチオニン(M)に置換した変異体のアミノ酸配列を表す。
配列番号79
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をチロシン(Y)に置換した変異体のアミノ酸配列を表す。
配列番号80
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をトリプトファン(W)に置換した変異体のアミノ酸配列を表す。
配列番号81
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の125位のプロリン(P)をフェニルアラニン(F)に置換した変異体のアミノ酸配列を表す。
配列番号82
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の117位のバリン(V)をロイシン(L)に置換した変異体のアミノ酸配列を表す。
配列番号83
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の117位のバリン(V)をイソロイシン(I)に置換した変異体のアミノ酸配列を表す。
配列番号84
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の118位のトレオニン(T)をセリン(S)に置換した変異体のアミノ酸配列を表す。
配列番号85
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の118位のトレオニン(T)をリジン(K)に置換した変異体のアミノ酸配列を表す。
配列番号86
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の119位のアルギニン(R)をリジン(K)に置換した変異体のアミノ酸配列を表す。
配列番号87
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の119位のアルギニン(R)をトレオニン(T)に置換した変異体のアミノ酸配列を表す。
配列番号88
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の120位のアスパラギン酸(D)をグルタミン酸(E)に置換した変異体のアミノ酸配列を表す。
配列番号89
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の120位のアスパラギン酸(D)をアラニン(A)に置換した変異体のアミノ酸配列を表す。
配列番号90
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の122位のグルタミン酸(E)をアスパラギン酸(D)に置換した変異体のアミノ酸配列を表す。
配列番号91
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の122位のグルタミン酸(E)をアラニン(A)に置換した変異体のアミノ酸配列を表す。
配列番号92
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の127位のアスパラギン酸(D)をグルタミン酸(E)に置換した変異体のアミノ酸配列を表す。
配列番号93
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の127位のアスパラギン酸(D)をアラニン(A)に置換した変異体のアミノ酸配列を表す。
配列番号94
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の128位のチロシン(Y)をフェニルアラニン(F)に置換した変異体のアミノ酸配列を表す。
配列番号95
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の128位のチロシン(Y)をトリプトファン(W)に置換した変異体のアミノ酸配列を表す。
配列番号96
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の129位のチロシン(Y)をフェニルアラニン(F)に置換した変異体のアミノ酸配列を表す。
配列番号97
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の129位のチロシン(Y)をトリプトファン(W)に置換した変異体のアミノ酸配列を表す。
配列番号98
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の130位のメチオニン(M)をフェニルアラニン(F)に置換した変異体のアミノ酸配列を表す。
配列番号99
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の130位のメチオニン(M)をイソロイシン(I)に置換した変異体のアミノ酸配列を表す。
配列番号100
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の131位のアスパラギン酸(D)をグルタミン酸(E)に置換した変異体のアミノ酸配列を表す。
配列番号101
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の131位のアスパラギン酸(D)をアラニン(A)に置換した変異体のアミノ酸配列を表す。
配列番号102
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の132位のバリン(V)をチロシン(Y)に置換した変異体のアミノ酸配列を表す。
配列番号103
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の132位のバリン(V)をセリン(S)に置換した変異体のアミノ酸配列を表す。
配列番号104
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の124位のイソロイシン(I)をバリン(V)に、126位のグリシン(G)をアラニン(A)に置換した変異体のアミノ酸配列を表す。
配列番号105
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の124位のイソロイシン(I)をバリン(V)に、126位のグリシン(G)をセリン(S)に置換した変異体のアミノ酸配列を表す。
配列番号106
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の121位のロイシン(L)をイソロイシン(I)に、123位のトリプトファン(W)をチロシン(Y)に、124位のイソロイシン(I)をバリン(V)に、126位のグリシン(G)をアラニン(A)に置換した変異体のアミノ酸配列を表す。
配列番号107
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の121位のロイシン(L)をイソロイシン(I)に、123位のトリプトファン(W)をチロシン(Y)に、124位のイソロイシン(I)をバリン(V)に、126位のグリシン(G)をセリン(S)に置換した変異体のアミノ酸配列を表す。
配列番号108
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の122位のグルタミン酸(E)を欠失させた変異体のアミノ酸配列を表す。
配列番号109
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の126位のグリシン(G)と127位のアスパラギン酸(D)の間にグルタミン酸(E)を挿入した変異体のアミノ酸配列を表す。
配列番号110
本発明の抗AD1抗体(EV2038)のH鎖のアミノ酸配列中の79位のアスパラギン(N)をグルタミン(Q)に置換した変異体のアミノ酸配列を表す。
配列番号111
実施例8で作製、使用した合成ペプチド(表5のペプチド1)のアミノ酸配列を表す。
配列番号112
実施例8で作製、使用した合成ペプチド(表5のペプチド2)のアミノ酸配列を表す。
配列番号113
実施例8で作製、使用した合成ペプチド(表5のペプチド3)のアミノ酸配列を表す。
配列番号114
実施例8で作製、使用した合成ペプチド(表5のペプチド4)のアミノ酸配列を表す。
配列番号115
実施例8で作製、使用した合成ペプチド(表5のペプチド5)のアミノ酸配列を表す。
配列番号116
実施例8で作製、使用した合成ペプチド(表5のペプチド6)のアミノ酸配列を表す。
配列番号117
実施例8で作製、使用した合成ペプチド(表5のペプチド7)のアミノ酸配列を表す。
配列番号118
実施例8で作製、使用した合成ペプチド(表5のペプチド8)のアミノ酸配列を表す。
配列番号119
実施例8で作製、使用した合成ペプチド(表5のペプチド9)のアミノ酸配列を表す。
配列番号120
実施例8で作製、使用した合成ペプチド(表5のペプチド10)のアミノ酸配列を表す。
配列番号121
実施例8で作製、使用した合成ペプチド(表5のペプチド11)のアミノ酸配列を表す。
配列番号122
実施例8で作製、使用した合成ペプチド(表5のペプチド12)のアミノ酸配列を表す。
配列番号123
実施例8で作製、使用した合成ペプチド(表5のペプチド13)のアミノ酸配列を表す。
配列番号124
実施例8で作製、使用した合成ペプチド(表5のペプチド14)のアミノ酸配列を表す。
配列番号125
実施例8で作製、使用した合成ペプチド(表5のペプチド15)のアミノ酸配列を表す。
配列番号126
実施例8で作製、使用した合成ペプチド(表5のペプチド16)のアミノ酸配列を表す。
配列番号127
実施例8で作製、使用した合成ペプチド(表5のペプチド17)のアミノ酸配列を表す。
配列番号128
実施例8で作製、使用した合成ペプチド(表5のペプチド18)のアミノ酸配列を表す。
配列番号129
実施例8で作製、使用した合成ペプチド(表5のペプチド19)のアミノ酸配列を表す。
配列番号130
実施例8で作製、使用した合成ペプチド(表5のペプチド20)のアミノ酸配列を表す。
配列番号131
実施例8で作製、使用した合成ペプチド(表5のペプチド21)のアミノ酸配列を表す。
配列番号132
実施例8で作製、使用した合成ペプチド(表5のペプチド22)のアミノ酸配列を表す。
配列番号133
実施例8で作製、使用した合成ペプチド(表5のペプチド23)のアミノ酸配列を表す。
配列番号134
実施例8で作製、使用した合成ペプチド(表5のペプチド24)のアミノ酸配列を表す。
配列番号135
実施例8で作製、使用した合成ペプチド(表5のペプチド25)のアミノ酸配列を表す。
配列番号136
実施例8で作製、使用した合成ペプチド(表5のペプチド26)のアミノ酸配列を表す。
配列番号137
ヒトサイトメガロウイルス(HCMV)のgB糖タンパク質のアミノ酸配列(Swiss-Prot: P06473)を表す。
本実施例において使用する手順は、特に言及しない限り、Molecular Cloning: A Laboratory Manual (Third Edition) (Sambrookら、Cold Spring Harbour Laboratory Press,2001)で参照することができる。
抗体産生細胞クローンの分離までのフローチャートを図1に示す。
血清中の抗HCMV抗体が高値であるヒトの末梢血からBリンパ球を分離し、EBVを感染させた。感染細胞を96ウェルプレートに播種し、およそ3週間培養した後、培養上清中の抗HCMV抗体のスクリーニングを行った(1次スクリーニング)。スクリーニングはHCMVの主要な中和エピトープであるAD1およびAD2(J. Virol., 65, 138-146 (1991), J. Gen. Virol., 73, 2375-2383 (1992), J. Virol., 66, 5290-5297 (1992), J. Virol., 67, 703-710 (1993))に対する抗体をターゲットとし、GST融合HCMV-AD1またはGST融合HCMV-AD2をコートした96ウェルプレートを用いて、ELISA法により行った。抗HCMV抗体産生が確認された各ウェルの細胞を希釈し、それぞれ新たな96ウェルプレートに播種した。約3週間培養後、抗HCMV抗体産生の2次スクリーニングを行った。得られた抗体陽性ウェルの細胞を、新たな96ウェルプレートにウェル当たり1~30ヶ播種した。この限界希釈培養によるクローニング操作の結果、目的抗体を産生している細胞クローンを得た。
分離した抗体産生細胞クローンの培養上清を用い、産生する抗体のアイソタイプをELISA法により確認した(文献:Curr Protoc Immunol. 2001 May; Chapter 2: Unit 2.2参照)。ELISAはGST融合HCMV-AD1またはAD2をコートした96ウェルプレートを用い、2次抗体としてそれぞれのアイソタイプおよびサブクラスに特異的な抗体を使用した。その結果、得られた抗HCMV抗体のアイソタイプおよびサブクラスを表2に示す。
抗体産生細胞のtotal-RNAから、Oligo-dTプライマーを用いて逆転写し、得られたcDNAを鋳型としてPCR法による抗体遺伝子の増幅を行った。PCRに使用したプライマーは、ヒトIgG抗体H鎖およびL鎖をコードするcDNAのデータベースをもとに設計した。完全長のH鎖cDNAおよびL鎖cDNAを増幅するため、5’末端側プライマーは翻訳開始点を、3’末端側プライマーは翻訳終止点を有している。
PCR法により増幅した抗体H鎖およびL鎖のcDNAをプラスミドベクターに挿入し、ABIシークエンサーによりそれぞれの塩基配列を確認した。得られた塩基配列より、シグナル配列、及び抗体H鎖およびL鎖のアミノ酸配列を決定した。
また、抗体の相補性決定領域(CDR)の解析には、Kabatの方法を用いた(www.bioinf.org.uk:Dr.Andrew C.R. Martin’s Group, Antibodies: General Information)。得られた抗HCMV抗体(EV2038)のCDR配列を配列番号13~18に示す。具体的には、EV2038のH鎖CDR1、H鎖CDR2、H鎖CDR3、L鎖CDR1、L鎖CDR2、およびL鎖CDR3のアミノ酸配列をそれぞれ配列番号13、14、15、16、17、および18に示す。
ところで、これまでにAD1抗体として報告されているモノクローナル抗体との類似性を調べるために、可変領域のアミノ酸配列がGenBank等に掲載されている抗体について、EV2038のCDR配列との比較を行った。既知のヒトまたはマウス由来のAD1抗体の各種CDR配列をKabat法で定め、同様に定めたEV2038のCDR配列とそれぞれ比較した。表3中、個々のCDRの相同性は、比較対象となるアミノ酸残基の数(分母)と当該CRD部分でEV2038と位置と種類が一致したアミノ酸残基の数(分子)から求めた相同性(%)である。また、全体(%)は、個々のCDRの比較で得られた分母となるアミノ酸残基の数と分子となるアミノ酸残基の数をそれぞれ合計し、得られた合計の分母および分子のアミノ酸残基数から相同性(%)を求めたものである。表3に示すようにEV2038は既知のAD1抗体とは相同性が全く認められず、これまで報告されているAD1抗体とはCDR配列に大きな差異があることが明らかになった。
得られたH鎖およびL鎖のcDNAをそれぞれ発現ベクターに挿入し、293T細胞に同時に導入した。遺伝子導入はリポフェクタミン(Invitrogen)とプラス試薬(Invitrogen)により、メーカー推奨条件で行った(Invitrogen のカタログ:Cat.No.18324-111, Cat.No.18324-012,またはCat.No.18324-020)。2日後に培養上清を回収し、抗ヒトIgG抗体およびGST融合HCMV-AD1をコートした96ウェルプレートを用いたELISA法により、培養上清中の抗体がヒトIgG抗体であること、およびHCMV-AD1に結合することを確認した。
得られた抗HCMV抗体発現プラスミドをCHO細胞に導入した。遺伝子導入は上述の293T細胞の場合と同様の方法を採用した。セレクションマーカー存在下で培養することにより、抗体を恒常的に産生するCHO細胞クローンを得た。
同抗体安定産生CHO細胞を無血清培地中で培養し、培養上清を回収した。この培養上清をProtein Aカラムに添加し、アフィニティー精製により精製抗体を得た。カラムはHiTrap rProteinA FF(GEヘルスケア社)のプレパックカラムを使用し、精製条件はカラムメーカー推奨条件とした。精製後、抗体のHCMV-AD1またはHCMV-AD2結合性をELISAにより確認した。また、SDS-PAGEによる約50kDaの抗体H鎖と約25kDaの抗体L鎖の確認を行った。
本発明の抗体又はその結合性断片の特性に影響するアミノ酸配列を検討すべく、特に、CDR-H3領域(アミノ酸番号117~132)について調べた。尚、CDR-H3のアミノ酸残基の番号は、配列番号2で示したシグナル配列も含む重鎖のアミノ酸配列のN末(メチオニン)からの順位でもって表記した。
EV2038のCDR-H3を構成している16残基のアミノ酸について2ステップPCR法を用いて各1種類ずつ非保存的アミノ酸置換を行ない、バリアント (V117K, T118W, R119V, D120I, L121E, E122L, W123T, I124D, P125R, G126F, D127I, Y128N, Y129N, M130Q, D131I, V132K)を作製した。まず、38Hind-S (CACCAAGCTTTGTGCAAGAACATGAAGCATC:配列番号19)と置換部位のリバースプライマーのペアで前半部の遺伝子断片を、置換部位フォワードプライマーと38Not-A (ATAAGAATGCGGCCGCGCCGTCGCACTCATTTACC:配列番号20)のペアで後半部の遺伝子断片を得た。これらを鋳型として2nd PCRを行ない、完全長のバリアント抗体遺伝子を得た。その後、抗体遺伝子をおよびNot Iの制限酵素処理にて末端を粘着にしたのち、抗体産生用プラスミドに組み込んだ。各バリアントの塩基配列の確認は塩基配列確認用プライマー(ACCAGACATAATAGCTGACAG:配列番号21)を使用し、3130 Genetic Analyzer(ABI社)を用いて推奨プロトコールに則り確認した。
得られたバリアントプラスミド(H鎖)をL鎖のオリジナルプラスミドとともにLipofectamine LTX (Invitrogen社) の推奨プロトコールに則り、CHO細胞に共遺伝子導入し、48時間後の培養上清を採取した。抗ヒトIgG抗体(0.25 μg/well)を固相化したImmuno plate (Maxi sorp, Nunc社)に対し、段階希釈した培養上清を室温で1時間反応させた。2次抗体として、抗ヒトイムノグロブリンGガンマおよび抗ヒトイムノグロブリンGラムダ(MBL社)を同じく室温で11時間反応させた。発色剤としてTMB基質を含むSure Blue (MPL社)を50μL/mL添加して室温で30分静置後、1.5Mリン酸を等量加え、マイクロプレートリーダー(680XR, BIO-RAD社)を用いて450 nmの吸光波長を測定した。ガンマ鎖とラムダ鎖の吸光度から抗体の有無と定量を行なった。
5μg/mLのAD1を固相化したImmuno plate (Poly sorp, Nunc社)に、ラムダ鎖を基準に1μg/mLの濃度に調整した抗体を希釈系列で反応させた。その後、先述と同様にELISAを行なった。得られたバリアントおよびEV2038(オリジナル)の450nmでの吸光度からバリアントのAD1抗原に対する結合能を評価した。その結果、EV2038 CDR-H3の122番目を除く121~126番目までの残基の非保存的なアミノ酸置換がAD1への結合能を著しく低下させたことから、これらの残基がAD1のパラトープとして重要であることが示唆された(図2)。
非保存的アミノ酸置換においてAD1に対する結合能が低下した5つのアミノ酸残基のうち、121番目,123番目,124番目,及び126番目の4箇所のアミノ酸残基については、むしろ特性の近似したアミノ酸への置換を試みた。使用したアミノ酸はそれぞれ5種類で、具体的には、(図3)に示したようなバリアントを作製した。尚、125番目のプロリンについてはオリジナル以外のすべての天然アミノ酸への置換を行なった(図4)。バリアントは先述のごとく作製した。
5 μg/mLの-AD1を固相化したImmuno plate (Poly sorp, Nunc社)に、ラムダ鎖を基準に1 μg/mLの濃度に調整した抗体を希釈系列で反応させた。その後、先述と同様にELISAを行ない、バリアントのAD1に対する結合能を評価した。121, 123, 124, 126番目のアミノ酸については、保存的アミノ酸に則ったアミノ酸置換では大部分がAD1に対する結合能を保持していた(図3)。しかし、125番目のプロリンについては他全ての天然型アミノ酸(19種類)による置換においてもAD1に対する結合能が認められることはなかった(図4)。このことから、本発明におけるEV2038のCDR-H3において、125番目のプロリンは当該抗体のAD1結合特性に必須のアミノ酸であることが示された。
非保存的アミノ酸置換においてAD1との結合能が低下しなかったアミノ酸残基(117~120番目、122番目、127~132番目の計11残基)について同様の方法で保存的アミノ酸置換についても実施し、AD1における結合能評価を確認した。その結果、この領域における保存的なアミノ酸置換を持つバリアント(V117L, V117I, T118S, T118K, R119K, R119T, D120E, D120A, E122D, E122A, D127E, D127A, Y128F, Y128W, Y129F, Y129W, M130F, M130I, D131E, D131A, V132Y, V132S)は非保存的アミノ酸置換時同様、AD1における結合能を保持していることが明らかになった(図5)。
非保存的アミノ酸置換においてAD1との結合能が低下したアミノ酸残基で125番のプロリンを除く残基(121, 123, 124,および 126番目の計4残基)を対象に2箇所若しくは4箇所を同時に置換したバリアントを計4種作製し(2箇所置換体:I124V/G126A, I124V/G126S,4箇所置換体: L121I/W123Y/I124V/G126A, L121I/W123Y/I124V/G126S)、AD1に対する結合能を評価した。その結果、これらの重複置換のバリアントは、いずれもAD1に対する結合能を保持していることが明らかになった(図6)。
非保存的アミノ酸置換においてAD1との結合能が低下したアミノ酸残基で125番のプロリンを除く残基(121, 123, 124,および 126番目の計4残基)を対象に欠失、挿入のバリアントを各1種作製し(E122del,および G126_D127insE)、AD1に対する結合能を評価した。その結果、E122delおよびG126_D127insEともにAD1に対する結合能が完全に消失した。このことから、この部位(121~126番)におけるアミノ酸残基の数(6残基)がAD1への結合に重要であることが示唆された(図7)。
XnXnXnXnX1XnX2X3PX4XnXnXnXnXnXn(配列番号22)
但し、Xn = 全ての天然型アミノ酸
X1 = L、I、V、FまたはA
X2 = W、YまたはF
X3 = I、V、LまたはM
X4 = G、S、AまたはT
CDR-H3以外の保存的な置換がAD1に対する結合能に影響するか否かを調べるために、EV2038のCDR-H2に位置するN79をN79Qにしたバリアントを他のバリアントと同様の方法で作製し、AD1に対する結合能を確認した。結果から、CDR-H2に位置するN79をN79Qにしたバリアントにおいても、AD1に対する結合能は失われないことが証明された(図8)。
これらAD1抗体のgB糖タンパク質上の結合部位を確認するために、HCMVgBのAD1がクローニングされた発現ベクターにPCR法で欠失変異を導入し、AD1の様々な部分が欠失したタンパク質を発現する大腸菌変異体シリーズを作製した。これらの変異体大腸菌を培養、発現誘導した後、セルライセートを抗原として標準的なウェスタンブロット分析を行った。対照としては、EV2038及び置換部位の異なるバリアントでAD1に対する結合能を有するものを代表として2種選択した。選択したバリアントの1つは、CDR-H3のループ構造(Shirai,H.,et al., FEBS Letters, 1996;399:p1-8)の上部に位置する124番目のイソロイシン部分(非保存的アミノ酸置換でAD1結合活性が認められなかった部位の1つ)の置換体で、その部位の保存的アミノ酸置換体I124Vである。他は、CDR-H3のループ構造の根元部分に位置する132番目のバリンの非保存的アミノ酸置換体V132Kである。
EV2038、I124V、およびV132Kは、いずれもクローン番号#0、#12、#13、#14、#15、および#19に結合し、EV2038およびそのバリアントは、いずれもアミノ酸残基549~580(SCVTINQTSVKVLRDMNVKESPGRCYSRPVVI:配列番号23)、および596~640(EDNEILLGNHRTEECQLPSLKIFIAGNSAYEYVDYLFKRMIDLSS:配列番号24)の間にエピトープが存在することが判明した(図9および10)。尚、抗原とするHCMV AD169株のgBのアミノ酸配列は、アクセッション番号P06473の配列を参照し開始コドンのメチオニンから順に番号をつけて表記した。
ところで、AD1領域を認識する抗体としては、ITC52等でアミノ酸残基570~579及びアミノ酸残基606~619の不連続エピトープを認識すること(WO93/21952 およびJ.Virol, 67; p703-710(1993))が報告されているが、少なくともアミノ酸残基569~576 (SPGRCYSR:配列番号26)を除いた2つのエピトープ配列部分は、過去のAD1抗体における報告では認められず、EV2038はこれまでに報告されているAD1抗体とは異なる不連続配列を認識する抗体であることが示された(図10)。
(1)免疫染色法
抗HCMV抗体(EV2038)の有効性評価として中和活性を確認した。中和活性はヒト胎児肺由来正常繊維芽細胞(MRC―5:理研BRC No.RCB0211)に対するHCMV(AD169株)感染の抗体による阻止率で評価した。方法はAbaiら(Journal of Immunological Methods 322 2007 82-93)に倣った。要約すると以下の通りである。ウイルス液と精製抗体に補体(5%)を加えて1時間おき、その後、MRC-5細胞に接種(37℃、1時間)した。細胞は2回洗浄し、20時間培養した後、HCMVの前早期タンパク質であるIE1を免疫蛍光染色により検出した。HCMV感染細胞の計測は画像解析ソフトImage J (http://rsbweb.nih.gov/ij/)で行なった。
前記評価で高い中和活性を示したEV2038について、更に、プラーク法(Masuho, Y. et al., J. Gen. Virol., 1987; 68: p1457-1461)での感染阻止活性を評価した。ウイルス株としてはHCMV実験室株として代表されるAD169、Towne、Davis、Merlin株およびHCMV臨床分離株であるT-137,MDU-1を使用した。方法を要約すると以下の通りである。50~100PFUのウイルス液と段階希釈した所定の濃度の精製抗体を混和し、37℃、1時間インキュベーションした後、48ウェルマイクロプレートで単層化した繊維芽細胞(MRC-5)または網膜色素上皮細胞(ARPE-19)に接種した。接種後、37℃、2時間インキュベーションした後、培養上清を除去し、2回洗浄した後、2% FCSを含む通常培地で37℃で培養した。ウイルス感染細胞の死による明瞭なプラークの形成が確認されるまで、実験室株で5~6日、臨床分離株で10~12日培養した後、5%ホルマリンを加えて細胞を固定し、0.025%クリスタルバイオレットで染色した。染色後、ウェルあたりのプラーク数を計数し、抗HCMV抗体の感染阻止率を算出した。
表7は、プラーク法によりEV2038の中和活性を評価した結果である。陰性コントロールにはHCMVに特異性を有しないヒトモノクローナル抗体(hIgG)を、陽性コントロールには米国において腎移植に伴うHCMV感染症の発症予防適応で承認されている抗CMV高力価免疫グロブリン製剤CytoGam(CSL Behring, CytoGam Cytomegalovirus immune globulin intravenous, Prescribing information. (Revised July 2008))を使用した。
HCMVは繊維芽細胞に対する感染様式と上皮細胞および内皮細胞に対する感染様式で侵入機構が異なることが報告されており(Sinzger, C. et al., Curr Top Microbiol Immunol., 2008; 325: p63-83)、AD169株およびTowne 株に代表される実験室株の多くは繊維芽細胞で複数回の継代を経たことで、上皮細胞および内皮細胞への感染性を失っているとされている(Dai Wang, et al., J. Virol., 2005; 79: p10330-10338)。一方で、本来HCMVは体内において広汎な組織および細胞種に感染性を有しており(Sinzger, C. et al., Curr Top Microbiol Immunol., 2008; 325: p63-83)、抗HCMV抗体が臨床効果を示す上では、繊維芽細胞型および上皮細胞・内皮細胞型のいずれのタイプが感染宿主細胞となっても、有効な中和活性を有することが重要であると考えられる。
本発明の抗HCMV抗体(EV2038)は、実験室株の繊維芽細胞への感染においてIC50で0.012- 0.037μg/mLを示すことを確認した。また、上皮細胞・内皮細胞への感染性を保存する臨床分離株(MDU-1)の繊維芽細胞への感染においてはIC50が0.044μg/mLであるのに対して、上皮細胞への感染においても0.040μg/mLと、繊維芽細胞型および上皮細胞・内皮細胞型のいずれの細胞種においても同等の優れた中和活性を有することを確認した。また、EV2038は、市販されている抗CMV高力価免疫グロブリン製剤CytoGamに比べてもAD169株に対して約2000倍も高活性であり、かつ臨床開発が行われた実績があるC23に対しても文献値(Masuho, Y. et al., J. Gen. Virol., 1987; 68: p1457-1461)より約20倍高活性であった。
EV2038のバリアントの中から置換部位の異なる2種類のバリアントを選択し中和活性を確認した。1つは、非保存的アミノ酸置換はでAD1結合活性が認められなかった124番目のイソロイシン部分(CDR-H3のループ構造の上部部分)のアミノ酸の置換体で、その部位の保存的アミノ酸置換体I124Vを用いた。他は、非保存的アミノ酸置換においてもオリジナルと同等のAD1結合活性が認められた132番目(CDR-H3のループ構造の根元部分)の非保存的アミノ酸置換体V132Kである。方法は前述のAbaiら(Journal of Immunological Methods 322 2007 82-93)に倣った。 陰性コントロールとしてはHCMVに特異性のないヒトモノクローナル抗体(hIgG)を、陽性コントロールとしてはCMVの中和エピトープの一つであるglycoprotein H (gH) に結合するマウスモノクローナル抗体(clone name HCMV16, AbD serotec : 2470-5437)を使用した。それぞれの抗体のHCMV感染阻止率を、同濃度のhIgGを加えた場合の感染阻止率に対するパーセントで求めた。50%阻害濃度(IC50)はI124Vが0.45μg/mL、V132Kが1.20μg/mLと、いずれもEV2038とほぼ同等の活性が認められた。
さらに、EV2038の有効性評価の一つとして、HCMVに感染したヒト胎児肺由来正常線維芽細胞(MRC-5)を用いて、EV2038の細胞間感染阻止活性について評価した。評価方法はNavarroら(Virology. 1993; 197: p143-158)の方法に準じた。具体的には、HCMV(AD169) を感染させて24時間経過したMRC-5を用い、抗体を10 mg/mL(約67nM)からの4倍希釈系列で加えた。細胞は感染6日後に固定し、感染早期発現タンパク質であるIE1を免疫染色により検出した。HCMV感染細胞の計測は画像解析ソフトImageJで行なった。その結果、抗AD1抗体であるEV2038を感染後の細胞に添加することによって、ウイルスの細胞間感染を顕著に阻害することが明らかとなった(表8)。
尚、表中 (1)+++は、100-75%の阻害、(2)++は、75-50%の阻害、(3)+は、50-25%の阻害、(4)±は、25-0%の阻害を示し、(5)-は、感染拡大阻害効果が認められなかったことを意味する。
Claims (20)
- ヒトサイトメガロウイルス(HCMV)gB糖タンパク質のAD1領域に結合する抗体もしくはその抗原結合性断片であって、AD1領域に存在する配列番号25のアミノ酸配列、配列番号26のアミノ酸配列、および配列番号27のアミノ酸配列から成る不連続配列をエピトープとして認識する、抗体もしくはその抗原結合性断片。
- ヒトサイトメガロウイルス(HCMV)gB糖タンパク質のAD1領域に特異的に結合し、その生物活性を中和し得るモノクローナル抗体であって、
(i)重鎖の可変領域が、
(a)配列番号13のアミノ酸配列、および配列番号13のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される重鎖CDR1のアミノ酸配列、
(b) 配列番号14のアミノ酸配列、および配列番号14のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される重鎖CDR2のアミノ酸配列、および、
(c)配列番号15のアミノ酸配列、配列番号15のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、および配列番号22で示されるアミノ酸配列からなる群から選択される重鎖CDR3のアミノ酸配列、ならびに
(ii)軽鎖の可変領域が、
(a)配列番号16のアミノ酸配列、および配列番号16のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される軽鎖CDR1のアミノ酸配列、
(b) 配列番号17のアミノ酸配列、および配列番号17のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される軽鎖CDR2のアミノ酸配列、および、
(c)配列番号18のアミノ酸配列、および配列番号18のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、またはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列からなる群から選択される軽鎖CDR3のアミノ酸配列、
を含有する抗体もしくはその抗原結合性断片。 - 請求項2に記載の抗体もしくはその抗原結合性断片であって、HCMV-gB糖タンパク質の549~580位の連続するアミノ酸残基からなるアミノ酸配列(配列番号23)および596~640位の連続するアミノ酸残基からなるアミノ酸配列(配列番号24)の領域に存在する2以上の不連続配列から成るエピトープに特異的に結合する、抗体もしくはその抗原結合性断片。
- 請求項2に記載の抗体もしくはその抗原結合性断片であって、HCMV-gB糖タンパク質のAD1領域にある配列番号25のアミノ酸配列、配列番号26のアミノ酸配列、および配列番号27のアミノ酸配列から成る不連続配列をエピトープとして認識する、抗体もしくはその抗原結合性断片。
- 請求項3または4に記載の抗体もしくはその抗原結合性断片であって、
(i)
(a)配列番号13のアミノ酸配列を含む重鎖CDR1のアミノ酸配列、
(b)配列番号14のアミノ酸配列を含む重鎖CDR2のアミノ酸配列、および、
(c)配列番号22のアミノ酸配列からなる群から選択される重鎖CDR3のアミノ酸配列、ならびに
(ii)
(a)配列番号16のアミノ酸配列を含む軽鎖CDR1のアミノ酸配列、
(b)配列番号17のアミノ酸配列を含む軽鎖CDR2のアミノ酸配列、および、
(c)配列番号18のアミノ酸配列を含む軽鎖CDR3のアミノ酸配列、
を含有する抗体もしくはその抗原結合性断片。 - 請求項5に記載の抗体もしくはその抗原結合性断片であって、
(i)
(a)配列番号13のアミノ酸配列を含む重鎖CDR1のアミノ酸配列、
(b)配列番号14のアミノ酸配列を含む重鎖CDR2のアミノ酸配列、および、
(c)配列番号15のアミノ酸配列を含む重鎖CDR3のアミノ酸配列、ならびに
(ii)
(a)配列番号16のアミノ酸配列を含む軽鎖CDR1のアミノ酸配列、
(b)配列番号17のアミノ酸配列を含む軽鎖CDR2のアミノ酸配列、および、
(c)配列番号18のアミノ酸配列を含む軽鎖CDR3のアミノ酸配列、
を含有する、抗体もしくはその抗原結合性断片。 - 請求項2に記載の抗体もしくはその抗原結合性断片であって、
(a) 配列番号10のアミノ酸配列、配列番号10のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、もしくはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、または配列番号10のアミノ酸配列と95%以上の同一性を有するアミノ酸配列からなる重鎖可変領域(HCVR)、ならびに
(b) 配列番号12のアミノ酸配列、配列番号12のアミノ酸配列中1~数個のアミノ酸残基の欠失、置換、挿入、付加、もしくはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、または配列番号12のアミノ酸配列と95%以上の同一性を有するアミノ酸配列からなる軽鎖可変領域(LCVR)を含有する、抗体もしくはその抗原結合性断片。 - 請求項7に記載の抗体もしくはその抗原結合性断片であって、
(a)配列番号10のアミノ酸配列を含む重鎖可変領域(HCVR)、および
(b) 配列番号12のアミノ酸配列を含む軽鎖可変領域(LCVR)を含有する、抗体もしくはその抗原結合性断片。 - 請求項2に記載の抗体もしくはその抗原結合性断片であって、
(a) 配列番号2もしくは6のアミノ酸配列、配列番号2もしくは6のアミノ酸配列において、1~数個のアミノ酸残基の欠失、置換、挿入、付加、もしくはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、または配列番号2もしくは6のアミノ酸配列と95%以上の同一性を有するアミノ酸配列で示される重鎖(H鎖)、ならびに
(b) 配列番号4もしくは8のアミノ酸配列、配列番号4もしくは8のアミノ酸配列において、1~数個のアミノ酸残基の欠失、置換、挿入、付加、もしくはこれらのいずれか2つ以上の組み合わせの変異を有するアミノ酸配列、または配列番号4もしくは8のアミノ酸配列と95%以上の同一性を有するアミノ酸配列で示される軽鎖(L鎖)を含有する、抗体もしくはその抗原結合性断片; - 請求項9に記載の抗体もしくはその抗原結合性断片であって、
(a)配列番号2または6のアミノ酸配列を含む重鎖(H鎖)、および
(b)配列番号4または8のアミノ酸配列を含む軽鎖(L鎖)を含有する、抗体もしくはその抗原結合性断片。 - 前記抗体がヒトモノクローナル抗体である、請求項1~10のいずれかに記載の抗体またはその抗原結合性断片。
- 前記抗体のクラス(サブクラス)がIgG1(λ)である、請求項1~11のいずれかに記載の抗体またはその抗原結合性断片。
- HCMVの実験室株(AD169)に対するヒト繊維芽細胞下での50%プラーク形成阻止濃度が0.05μg/mL(約0.3nM)以下である請求項1~12のいずれかに記載の抗体またはその抗原結合性断片。
- ヒト繊維芽細胞(MRC-5)にあらかじめHCMVの実験室株(AD169)を感染させた系で、0.2μg/mL(約1.3nM)以下で50%以上の細胞間感染阻止能を有する請求項1~13のいずれかに記載の抗体またはその抗原結合性断片。
- 請求項1~14のいずれかに記載の抗体またはその抗原結合性断片および薬学的に許容可能な担体を含む、ヒトサイトメガロウイルス(HCMV)が関与する疾患を予防または治療するための医薬組成物。
- HCMVが関与する疾患が、(a)免疫不全状態におけるHCMVの再活性化による間質性肺炎、網膜炎、胃腸炎、もしくは脳炎、(b)妊婦から胎児へHCMV感染が波及することによる先天性CMV感染症、(c)前記先天性CMV感染症により引き起こされる流産、死産、生後間もない死亡、(d)前記先天性CMV感染症により死亡しない場合における低出生体重、肝脾腫、黄疸、血小板減少性紫斑病、小頭症、精神発育障害、知能発達遅延、脈絡網膜炎、もしくは聴覚障害、または(e)新生児もしくは乳児期におけるHCMV感染により発症する肝機能異常、間質性肺炎、もしくは単核症である、請求項15に記載の医薬組成物。
- HCMVgB糖タンパク質のAD1領域に特異的に結合し、その生物活性を中和し得る抗HCMVモノクローナル抗体またはその抗原結合性断片をコードする核酸であって、配列番号2、4、6、8、10、12、13~18、および22からなる群から選択されるアミノ酸配列をコードする核酸、および該核酸と高ストリンジェントな条件下でハイブリダイズする核酸から選択される単離された核酸。
- 請求項17に記載の核酸を組込んだベクター。
- 請求項18に記載のベクターが導入された宿主細胞。
- 請求項19に記載の宿主細胞を培養する工程を含む、請求項1~14のいずれかに記載の抗体または抗原結合性断片の作製方法。
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2011010382A MX2011010382A (es) | 2009-04-01 | 2010-04-01 | Anticuerpo monoclonal capaz de unirse a epitopo discontinuo especifico que ocurre en la region ad1 de la glicoproteina gb de citomegalovirus humano y fragmento de union a antigeno del mismo. |
ES10758877.4T ES2539751T3 (es) | 2009-04-01 | 2010-04-01 | Anticuerpo monoclonal capaz de unirse con epítopo discontinuo específico que aparece en la región AD1 de la glucoproteína gB de citomegalovirus humano, y fragmento de unión a antígeno del mismo |
RU2011144113/10A RU2542472C2 (ru) | 2009-04-01 | 2010-04-01 | Моноклональное антитело, способное связываться со специфическим прерывистым эпитопом, расположенным в области ad1 гликопротеина gb цитомегаловируса человека, и его антигенсвязывающий фрагмент |
BRPI1013648-7A BRPI1013648B1 (pt) | 2009-04-01 | 2010-04-01 | Anticorpo ou fragmento de ligação de antígeno, composição farmacêutica e método para produção do anticorpo ou o fragmento de ligação de antígeno |
AU2010232202A AU2010232202B2 (en) | 2009-04-01 | 2010-04-01 | Monoclonal antibody capable of binding to specific discontinuous epitope occurring in AD1 region of human cytomegalovirus gB glycoprotein, and antigen-binding fragment thereof |
DK10758877.4T DK2420572T3 (en) | 2009-04-01 | 2010-04-01 | MONOCLONAL ANTIBODY THAT CAN BIND TO SPECIFIC discontinuous EPITOPE, OCCURRING IN AD 1 REGION OF HUMAN cytomegalovirus GB-glycoprotein AND ANTIBODY-binding fragment thereof. |
SI201030942T SI2420572T1 (sl) | 2009-04-01 | 2010-04-01 | Monoklonsko protitelo, ki je sposobno vezave na specifični diskontinuirani epitop, ki se pojavi pri regiji ad1 glikoproteina gb človeškega citomegalovirusa, in njegov antigen-vezavni fragment |
US13/262,061 US8492529B2 (en) | 2009-04-01 | 2010-04-01 | Monoclonal antibody capable of binding to specific discontinuous epitope occurring in AD1 region of human cytomegalovirus GB glycoprotein, and antigen-binding fragment thereof |
EP10758877.4A EP2420572B1 (en) | 2009-04-01 | 2010-04-01 | Monoclonal antibody capable of binding to specific discontinuous epitope occurring in ad1 region of human cytomegalovirus gb glycoprotein, and antigen-binding fragment thereof |
JP2011507298A JP4981192B2 (ja) | 2009-04-01 | 2010-04-01 | ヒトサイトメガロウイルスgB糖タンパク質のAD1領域に存在する特定の不連続エピトープに結合するモノクローナル抗体ならびにその抗原結合性断片 |
KR1020117025880A KR101390015B1 (ko) | 2009-04-01 | 2010-04-01 | 인간 사이토메갈로바이러스 gB 당단백질의 AD1 영역에 존재하는 특정한 불연속 에피토프에 결합하는 모노클로날 항체 및 그의 항원 결합성 단편 |
CN2010800149887A CN102378814B (zh) | 2009-04-01 | 2010-04-01 | 与存在于人巨细胞病毒gB糖蛋白的AD1区域的特定的不连续表位结合的单克隆抗体及其抗原结合片段 |
CA2756889A CA2756889C (en) | 2009-04-01 | 2010-04-01 | Monoclonal antibody capable of binding to specific discontinuous epitope occurring in ad1 region of human cytomegalovirus gb glycoprotein, and antigen-binding fragment thereof |
IL215439A IL215439A (en) | 2009-04-01 | 2011-09-27 | A monoclonal antibody that can bind to a specific non-continuous epitope located in the 1ad region of human cytomegalovirus gb glycoprotein and its antigen-binding site |
HRP20150623TT HRP20150623T1 (hr) | 2009-04-01 | 2015-06-10 | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-089442 | 2009-04-01 | ||
JP2009089442 | 2009-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010114106A1 true WO2010114106A1 (ja) | 2010-10-07 |
Family
ID=42828394
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/056037 WO2010114106A1 (ja) | 2009-04-01 | 2010-04-01 | ヒトサイトメガロウイルスgB糖タンパク質のAD1領域に存在する特定の不連続エピトープに結合するモノクローナル抗体ならびにその抗原結合性断片 |
PCT/JP2010/056033 WO2010114105A1 (ja) | 2009-04-01 | 2010-04-01 | ヒトサイトメガロウイルスgB糖タンパク質のAD2領域に結合するモノクローナル抗体ならびにその抗原結合性断片 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/056033 WO2010114105A1 (ja) | 2009-04-01 | 2010-04-01 | ヒトサイトメガロウイルスgB糖タンパク質のAD2領域に結合するモノクローナル抗体ならびにその抗原結合性断片 |
Country Status (16)
Country | Link |
---|---|
US (1) | US8492529B2 (ja) |
EP (1) | EP2420572B1 (ja) |
JP (1) | JP4981192B2 (ja) |
KR (1) | KR101390015B1 (ja) |
CN (1) | CN102378814B (ja) |
AU (1) | AU2010232202B2 (ja) |
BR (1) | BRPI1013648B1 (ja) |
CA (1) | CA2756889C (ja) |
DK (1) | DK2420572T3 (ja) |
ES (1) | ES2539751T3 (ja) |
HR (1) | HRP20150623T1 (ja) |
IL (1) | IL215439A (ja) |
MX (1) | MX2011010382A (ja) |
RU (1) | RU2542472C2 (ja) |
SI (1) | SI2420572T1 (ja) |
WO (2) | WO2010114106A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011076883A1 (en) | 2009-12-23 | 2011-06-30 | 4-Antibody Ag | Binding members for human cytomegalovirus |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
RU2738001C1 (ru) * | 2020-03-23 | 2020-12-07 | Борис Сергеевич Першин | Способ определения риска развития цитомегаловирусного (ЦМВ) ретинита после трансплантации гемопоэтических стволовых клеток |
WO2021110126A1 (zh) | 2019-12-04 | 2021-06-10 | 珠海泰诺麦博生物技术有限公司 | 抗人巨细胞病毒抗体及其用途 |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
WO2013177118A2 (en) * | 2012-05-21 | 2013-11-28 | Abbvie Inc. | Novel purification of non-human antibodies using protein a affinity chromatography |
US20140154270A1 (en) * | 2012-05-21 | 2014-06-05 | Chen Wang | Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
WO2014061783A1 (ja) | 2012-10-19 | 2014-04-24 | 株式会社イーベック | クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片 |
EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2023039242A2 (en) * | 2021-09-13 | 2023-03-16 | Achelois Biopharma, Inc. | Multivalent interferon particles compositions and methods of use |
CN114853886B (zh) * | 2022-05-23 | 2023-11-28 | 南昌大学 | 一种高亲和力抗人巨细胞病毒的全人源单克隆抗体及其用途 |
CN116162154B (zh) * | 2022-10-21 | 2024-06-11 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987003602A1 (en) | 1985-12-06 | 1987-06-18 | Teijin Limited | Anticytomegaloviral human monoclonal antibody and process for its preparation |
WO1993021952A1 (en) | 1992-04-23 | 1993-11-11 | Bioinvent International Ab | Human monoclonal antibodies against cytomegalovirus and method for preparation thereof |
JPH08502403A (ja) | 1992-10-15 | 1996-03-19 | スコットゲン リミティド | 組換ヒト型サイトメガロウィルス抗体 |
JPH08506325A (ja) | 1993-01-28 | 1996-07-09 | サンド ファーマスーティカル コーポレーション | サイトメガロウイルスに対するヒトモノクローナル抗体 |
WO2007094423A1 (ja) | 2006-02-15 | 2007-08-23 | Evec Incorporated | ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750106A (en) | 1993-01-28 | 1998-05-12 | Novartis Ag | Human monoclonal antibodies to cytomegalovirus |
JPH0859509A (ja) * | 1994-08-16 | 1996-03-05 | Teijin Ltd | サイトメガロウイルス抗原血症治療剤およびサイトメガロウイルス感染症治療剤 |
AUPR593101A0 (en) * | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
RU2239453C2 (ru) * | 2002-12-03 | 2004-11-10 | Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" | Препарат иммуноглобулина человека против цитомегаловируса и способ его получения |
AU2006322445B2 (en) * | 2005-12-05 | 2011-05-12 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
WO2009003975A1 (en) | 2007-07-04 | 2009-01-08 | Ribovax Biotechnologies Sa | Antibodies against human cytomegalovirus (hcmv) |
EP2190876A1 (en) | 2007-08-22 | 2010-06-02 | Ribovax Biotechnologies SA | Antibodies against human cytomegalovirus (hcmv) |
-
2010
- 2010-04-01 BR BRPI1013648-7A patent/BRPI1013648B1/pt active IP Right Grant
- 2010-04-01 CA CA2756889A patent/CA2756889C/en active Active
- 2010-04-01 EP EP10758877.4A patent/EP2420572B1/en active Active
- 2010-04-01 CN CN2010800149887A patent/CN102378814B/zh active Active
- 2010-04-01 MX MX2011010382A patent/MX2011010382A/es active IP Right Grant
- 2010-04-01 WO PCT/JP2010/056037 patent/WO2010114106A1/ja active Application Filing
- 2010-04-01 SI SI201030942T patent/SI2420572T1/sl unknown
- 2010-04-01 WO PCT/JP2010/056033 patent/WO2010114105A1/ja active Application Filing
- 2010-04-01 ES ES10758877.4T patent/ES2539751T3/es active Active
- 2010-04-01 JP JP2011507298A patent/JP4981192B2/ja active Active
- 2010-04-01 RU RU2011144113/10A patent/RU2542472C2/ru active
- 2010-04-01 US US13/262,061 patent/US8492529B2/en active Active
- 2010-04-01 KR KR1020117025880A patent/KR101390015B1/ko active IP Right Grant
- 2010-04-01 AU AU2010232202A patent/AU2010232202B2/en active Active
- 2010-04-01 DK DK10758877.4T patent/DK2420572T3/en active
-
2011
- 2011-09-27 IL IL215439A patent/IL215439A/en active IP Right Grant
-
2015
- 2015-06-10 HR HRP20150623TT patent/HRP20150623T1/hr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987003602A1 (en) | 1985-12-06 | 1987-06-18 | Teijin Limited | Anticytomegaloviral human monoclonal antibody and process for its preparation |
WO1993021952A1 (en) | 1992-04-23 | 1993-11-11 | Bioinvent International Ab | Human monoclonal antibodies against cytomegalovirus and method for preparation thereof |
JPH08502403A (ja) | 1992-10-15 | 1996-03-19 | スコットゲン リミティド | 組換ヒト型サイトメガロウィルス抗体 |
JPH08506325A (ja) | 1993-01-28 | 1996-07-09 | サンド ファーマスーティカル コーポレーション | サイトメガロウイルスに対するヒトモノクローナル抗体 |
WO2007094423A1 (ja) | 2006-02-15 | 2007-08-23 | Evec Incorporated | ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
Non-Patent Citations (50)
Title |
---|
"CSL Behring, CytoGam Cytomegalovirus immune globulin intravenous", PRESCRIBING INFORMATION, July 2008 (2008-07-01) |
"Curr Protoc Immunol.", May 2001 |
"Package insert for anti-cytomegalovirus chemotherapeutic agent, Denosine for intravenous infusion, 500 mg, ganciclovir formulation", October 2007, MITSUBISHI TANABE PHARMA |
"Package insert for anti-cytomegalovirus chemotherapeutic agent, Valixa tablet (4500 mg), valganciclovir hydrochloride formulation", October 2007, MITSUBISHI TANABE PHARMA |
"Package insert for antiviral agent for drip injection, Foscavir, 24 mg/mL, foscarnet sodium hydrate injection", June 2007, ASTRAZENECA |
ABAI ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 322, 2007, pages 82 - 93 |
ALTSCHUL SF ET AL., J MOL BIOL, vol. 215, 1990, pages 403 |
BRITT, W.J. ET AL.: "Antigenic domain is required for oligomerization of human cytomegalovirus glycoprotein B", J.VIROL., vol. 79, 2005, pages 4066 - 4079 |
DAI WANG ET AL., J. VIROL., vol. 79, 2005, pages L0330 - 10338 |
DAVISON, A.J. ET AL.: "The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome", J. GEN. VIROL., vol. 84, 2003, pages L7 - 28 |
DEMMLER, G.J.: "Congential cytomegalovirus infection and disease. Seminars in Pediatric Infection Diseases", SEMINARS IN PEDIATRIC INFECTIOUS DISEASES, vol. 10, 1999, pages 195 - 200 |
DOLAN, A. ET AL.: "Genetic content of wild-type human cytomegalovirus", J. GEN. VIROL., vol. 85, 2004, pages 130I - 1312 |
FREITAS,VR. ET AL.: "Activity of 9-(1,3-dihydroxy-2-Propoxymethel)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses", ANTI. AGENT CHEMO., vol. 28, 1985, pages 240 - 245 |
GRIFFITHS, P.D.: "The treatment of cytomegalovirus infection", J. ANTI. CHEMO., vol. 49, 2002, pages 243 - 253 |
ISAACSON, M.K. ET AL.: "Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress", J.VIROLOGY, vol. 83, 2009, pages 3891 - 3903 |
J. GEN. VIROL., vol. 73, 1992, pages 2375 - 2383 |
J. VIROL., vol. 65, 1991, pages 138 - 146 |
J. VIROL., vol. 66, 1992, pages 5290 - 5297 |
J. VIROL., vol. 67, 1993, pages 703 - 710 |
J.SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS, article "Conditions for Hybridization of Oligonucleotide Probes" |
J.VIROL, vol. 67, 1993, pages 703 - 710 |
KANDA S. ET AL., GLYCOBIOLOGY, vol. 17, 2007, pages 104 - 118 |
KARLIN, ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268 |
KEIKO TAYA: "Discussion of Infection: Cytomegalovirus infection", INFECTIOUS DISEASES WEEKLY REPORT JAPAN, vol. 15, 2003, pages 10 - 14 |
KIMBERLIN,D. W ET AL.: "Effect of ganciclovir therapy on hearing in symptomatic congental cytomegalovirus disease involving the central nervous system; randomized, controlled trial", J. PEDIATR., vol. 143, 2003, pages 16 - 25 |
KNIESS, N. ET AL.: "Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus", JOURNAL OF VIROLOGY, vol. 65, no. 1, 1991, pages 138 - 46, XP008153627 * |
MASUHO, Y ET AL., J. GEN. VIROL., vol. 68, 1987, pages 1457 - 1461 |
MASUHO, Y. ET AL., J. GEN. VIROL., vol. 68, 1987, pages L457 - 1461 |
MASUHO,T.: "Human monoclonal antibodies neutralizing human cytomegalovirus", J.GEN.VIROL, vol. 68, 1987, pages L457 - 1461 |
NATURE, vol. 312, 1984, pages 643 |
NATURE, vol. 321, 1986, pages 522 |
NAVARRO ET AL., VIROLOGY, vol. 197, 1993, pages L43 - 158 |
NAVARRO, D. ET AL.: "Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells", VIROLOGY, vol. 197, 1993, pages L43 - 158 |
NAVARRO, D. ET AL.: "Glycoprotein B of human Cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells", VIROLOGY, vol. 197, no. 1, 1993, pages 143 - 158, XP003017135 * |
NIWA R. ET AL., CLIN.CANCER RES., vol. 10, 2004, pages 6248 - 6255 |
OHIZUMI, Y. ET AL.: "Neutralizing mechanisms of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130/55", JOURNAL OF GENERAL VIROLOGY, vol. 73, no. 10, 1992, pages 2705 - 2707, XP008154082 * |
OHIZUMI, Y.: "Neutralizing mechanism of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130/55", J. GEN. VIROL., vol. 73, 1992, pages 2705 - 2707 |
OHLIN, M. ET AL.: "Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies", JOURNAL OF VIROLOGY, vol. 67, no. 2, 1993, pages 703 - 710, XP002544755 * |
OMASA T., J. BIOSCI. BIOENG., vol. 94, 2002, pages 600 - 605 |
PROC NATL ACAD SCI USA, vol. 90, 1993, pages 5873 |
PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268 |
QADRI, I. ET AL.: "Assembly of conformational-dependent neutralizing domains on glycoprotein B of human cytomegalovirus", J.GEN.VIROL, vol. 73, 1992, pages 2913 - 2921 |
RIECHMANN L ET AL.: "Reshaping human antibodies for therapy", NATURE, vol. 332, 1988, pages 323 - 327 |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual(Third Edition)", 2001, COLD SPRING HARBOUR LABORATORY PRESS |
See also references of EP2420572A4 |
SINZGER, C. ET AL., CURR TOP MICROBIOL IMMUNOL., vol. 325, 2008, pages 63 - 83 |
SINZGER, C. ET AL., CURR TOP MICROBIOL TMMUNOL., vol. 325, 2008, pages 63 - 83 |
WAGNER ET AL., JOURNAL OF VIROLOGY, vol. 66, no. 9, September 1992 (1992-09-01), pages 5290 - 5297 |
WAGNER, B. ET AL.: "A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus", JOURNAL OF VIROLOGY, vol. 66, no. 9, 1992, pages 5290 - 5297, XP003017153 * |
YASUGI, RYUITI, KOZEKI, HARUO, HURUYA, MASAKI, HIDAKA, TOSITAKA: "Iwanami Biological Dictionary", 1996 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011076883A1 (en) | 2009-12-23 | 2011-06-30 | 4-Antibody Ag | Binding members for human cytomegalovirus |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
WO2021110126A1 (zh) | 2019-12-04 | 2021-06-10 | 珠海泰诺麦博生物技术有限公司 | 抗人巨细胞病毒抗体及其用途 |
JP2023505514A (ja) * | 2019-12-04 | 2023-02-09 | トリノマブ バイオテック カンパニー リミテッド | 抗ヒトサイトメガロウイルス抗体及びその用途 |
JP7458484B2 (ja) | 2019-12-04 | 2024-03-29 | チューハイ トリノマブ ファーマシューティカル カンパニー リミテッド | 抗ヒトサイトメガロウイルス抗体及びその用途 |
RU2738001C1 (ru) * | 2020-03-23 | 2020-12-07 | Борис Сергеевич Першин | Способ определения риска развития цитомегаловирусного (ЦМВ) ретинита после трансплантации гемопоэтических стволовых клеток |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
Also Published As
Publication number | Publication date |
---|---|
US20120093810A1 (en) | 2012-04-19 |
JPWO2010114106A1 (ja) | 2012-10-11 |
CN102378814B (zh) | 2013-06-12 |
HRP20150623T1 (hr) | 2015-07-03 |
KR101390015B1 (ko) | 2014-04-29 |
BRPI1013648A2 (pt) | 2020-09-15 |
JP4981192B2 (ja) | 2012-07-18 |
RU2011144113A (ru) | 2013-05-10 |
EP2420572A1 (en) | 2012-02-22 |
ES2539751T3 (es) | 2015-07-03 |
BRPI1013648B1 (pt) | 2023-05-09 |
IL215439A0 (en) | 2011-12-29 |
RU2542472C2 (ru) | 2015-02-20 |
EP2420572A4 (en) | 2013-01-23 |
MX2011010382A (es) | 2012-01-12 |
IL215439A (en) | 2016-03-31 |
KR20120035142A (ko) | 2012-04-13 |
CA2756889C (en) | 2017-09-05 |
CA2756889A1 (en) | 2010-10-07 |
AU2010232202B2 (en) | 2013-08-29 |
US8492529B2 (en) | 2013-07-23 |
DK2420572T3 (en) | 2015-06-15 |
WO2010114105A1 (ja) | 2010-10-07 |
SI2420572T1 (sl) | 2015-10-30 |
CN102378814A (zh) | 2012-03-14 |
AU2010232202A1 (en) | 2011-10-27 |
EP2420572B1 (en) | 2015-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4981192B2 (ja) | ヒトサイトメガロウイルスgB糖タンパク質のAD1領域に存在する特定の不連続エピトープに結合するモノクローナル抗体ならびにその抗原結合性断片 | |
US8153129B2 (en) | Antibodies against human cytimegalovirus (HCMV) | |
WO2017059878A1 (en) | Antibodies that potently neutralize hepatitis b virus and uses thereof | |
US10759847B2 (en) | Antibodies that potently neutralize RSV and uses thereof | |
WO2009024445A1 (en) | Antibodies against human cytomegalovirus (hcmv) | |
US20100074906A1 (en) | Antibodies Specific for Varicella Zoster Virus | |
KR20220121820A (ko) | 인간 사이토메갈로바이러스에 대한 항체 및 이의 용도 | |
WO2014115893A1 (ja) | ヒト・メタニューモウイルスに特異的なヒト抗体もしくはその抗原結合性断片 | |
CN112778413A (zh) | 抗水痘-带状疱疹病毒的抗体 | |
JP2024509933A (ja) | 抗水痘帯状疱疹ウイルスの抗体およびその使用 | |
WO2010074218A1 (ja) | 抗ヒトミッドカイン抗体 | |
CN116162154B (zh) | 抗人巨细胞病毒抗体及其用途 | |
WO2022250107A1 (ja) | SARS-CoV-2野生株および変異株に対するヒト中和抗体およびその抗原結合性断片 | |
WO2023008463A1 (ja) | SARS-CoV-2野生株および変異株に対する中和ヒト抗体およびその抗原結合性断片 | |
Landolfo | Gribaudo, Giorgio | |
NZ578413A (en) | Antibodies against human cytomegalovirus (hcmv) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080014988.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10758877 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2756889 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011507298 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/010382 Country of ref document: MX Ref document number: 12011501974 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7306/CHENP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010758877 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010232202 Country of ref document: AU Date of ref document: 20100401 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20117025880 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011144113 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13262061 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1013648 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1013648 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110930 |